 
 
Official Title:  Treatment for Migraine and Mood (Team -M): A Pilot Trial of a 
Mindfulness -based Training Program   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  20-01911  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • March 13, 2022  
 
 
  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authori zed 
in writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  
 
  
 
 
Study Title:  TREATMENT FOR MIGRAINE AND MOOD (TEAM -M): A 
RANDOMIZED CONTROLLED TRIAL OF A MINDFULNESS -
BASED TRAINING PROGRAM  
NYULH Study Number  s20-01911  
Principal Investigator : 
 Dr. Amanda Shallcross, ND, MPH  
NYU Langone Health  
Department of Population Health  
180 Madison Ave., New York NY 10016  
Amanda.shallcross@nyulangone.org  
646-501-3426  
Additional Investigator s: Dr. Elizabeth Seng, PhD  
Yeshiva University  
Ferkauf Graduate School of Psychology  
1165 Morris Park Avenue, Rousso Building 
Bronx, NY 10461  
Elizabeth.Seng@yu.edu   
646-592-4368  
 
Dr. Rebecca Wells, MD, MPH  
Wake Forest Baptist Health Department of Neurology  
Medical Center Boulevard 9th Floor  
Winston- Salem, NC 27157 
336-716-9810  
rewells@wakehealth.edu   
 
Dr. Mia Minen , MD, MPH  
NYU Langone Health  
222 E 41st St  
New York, NY 10017  
(212) 263- 7744  
Mia.Minen@nyulangone.org  
 
Dr. Richard Lipton , MD  
1300 Morris Park Ave  
Bronx, NY 10461  
(718) 430- 3886  
richard.lipton@einsteinmed.edu  
 
 
ClinicalTrials.gov  Numbe r [STUDY_ID_REMOVED]  
 
Initial version:  3/8/2022
 
 
  
Study number:  s20-01911   Page ii 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authori zed 
in writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Statement of Complia nce 
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection 
of Human Subjects (45 CFR Part 46), any other applicable US government research regulations, 
and institutional research policies and procedures. The Principal Investigator will assure that no 
deviation from, or changes to the protocol will take place without prior agreement from the sponsor 
and documented approval from the Institutional Review Board (IRB), except where necessary to 
eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of 
this study have completed Human Subjects Protection Training.  
  
Study number:  s20-01911   Page iii 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authori zed 
in writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019   
Table of Contents  
 
1 KEY ROLES  ......................................................................................................................................... 1  
2 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONAL E ....................... 2  
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ................................................................ 2  
2.2 RATIONALE  .................................................................................................................................... 2  
2.3 POTENTIAL RISKS & BENEFITS  ........................................................................................................ 3  
2.3.1  Known Potential Risks  ............................................................................................................. 3  
2.3.2  Known Potential Benefits  ........................................................................................................ 3  
3 OBJECTIVES AND PURPO SE ........................................................................................................... 4  
4 STUDY DESIGN AND ENDPOINTS .................................................................................................... 4  
4.1 DESCRIPTION OF STUDY DESIGN  .................................................................................................... 4  
5 STUDY ENROLLMENT AND WITHDRAWAL  .................................................................................... 5  
5.1 INCLUSION CRITERIA  ...................................................................................................................... 5  
5.2 EXCLUSION CRITERIA  ..................................................................................................................... 5  
5.3 VULNERABLE SUBJECTS  ................................................................................................................. 5  
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  ............................................................................ 5  
5.4.1  Referrals from Clinician Co- Investigator and NYU -Affiliated Specialist  .................................. 5  
5.4.2  Use of DataCore/EPIC Information for Recruitment Purposes  ............................................... 6  
5.5 DURATION OF SUBJECT PARTICIPATION  ........................................................................................... 7  
5.6 TOTAL NUMBER OF SUBJECTS AND SITES........................................................................................ 7  
5.7 SUBJECT WITHDRAWAL OR TERMINATION  ........................................................................................ 7  
5.7.1  Reasons for Withdrawal or Termination  .................................................................................. 7  
5.7.2  Premature Termination or Suspension of Study  ..................................................................... 7  
6 PSYCHOLOGICAL INTERVENTION  .................................................................................................. 7  
6.1 INTERVENTION DESCRIPTION  .......................................................................................................... 7  
6.1.1  Administration of Intervention  .................................................................................................. 8  
6.1.2  Make- Up Session Protocol  ...................................................................................................... 8  
6.1.3  Procedures for Training Interventionalists and Monitoring Intervention Fidelity  ..................... 8  
6.1.4  Assessment of Subject Compliance with Study Intervention  .................................................. 8  
7 STUDY SCHEDULE AND P ROCEDURES  ......................................................................................... 9  
7.1 STUDY SCHEDULE  .......................................................................................................................... 9  
7.1.1  Pre-screening (online)  ............................................................................................................. 9  
7.1.2  Further Eligibility Screening (phone)  ....................................................................................... 9  
7.1.3  28-Day Baseline Run- In .......................................................................................................... 9  
7.1.4  Intervention Assignment & Intervention Orientation  ................................................................ 9  
7.1.5  Baseline/M0  ............................................................................................................................. 9  
7.1.6  Study Intervention  ................................................................................................................... 9  
7.1.7  Mid-intervention/M1  ............................................................................................................... 10 
7.1.8  Post-intervention/M2  ............................................................................................................. 10 
7.1.9  M3 .......................................................................................................................................... 10 
7.1.10  M6 .......................................................................................................................................... 10 
7.1.11  M9 .......................................................................................................................................... 10 
7.2 STUDY PROCEDURES AND EVALUATIONS  ...................................................................................... 10 
7.2.1  Study Specific Procedures  .................................................................................................... 10 
7.2.2  Concomitant Medications, Treatments, and Procedures  ...................................................... 21 
7.2.3  Post-Intervention Materials  .................................................................................................... 21 
8 ASSESSMENT OF SAFETY  ............................................................................................................. 21 
Study number:  s20-01911   Page iv 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authori zed 
in writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  8.1 SPECIFICATION OF SAFETY PARAMETERS  ...................................................................................... 21 
8.1.1  Definition of Adverse Events (AE)  ......................................................................................... 22  
8.1.2  Definition of Serious Adverse Events (SAE)  ......................................................................... 22  
8.1.3  Definition of Unanticipated Problems (UP)  ............................................................................ 23  
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ....................................................................................... 23  
8.2.1  Severity of Event  ................................................................................................................... 23  
8.2.2  Relationship to Study Intervention ......................................................................................... 23  
8.2.3  Expectedness  ........................................................................................................................ 23  
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP .................................... 24  
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB .......................................................................... 24  
8.5 REPORTING PROCEDURES – NOTIFYING THE STUDY SPONSOR  ...................................................... 24  
8.6 SAFETY OVERSIGHT  ..................................................................................................................... 25  
9 STATISTICAL CONSIDER ATIONS  .................................................................................................. 25  
9.1 DESCRIPTION OF STATISTICAL METHODS  ...................................................................................... 25  
9.2 MEASURES TO MINIMIZE BIAS ....................................................................................................... 28  
9.2.1  Enrollment /Masking Procedures  .......................................................................................... 28  
10 QUALITY ASSURANCE AN D QUALITY CONTROL  ....................................................................... 29  
11 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ............................................................................. 29  
11.1  ETHICAL STANDARD  ..................................................................................................................... 29  
11.2  INSTITUTIONAL REVIEW BOARD  ..................................................................................................... 29  
11.2.1  Independent (non- NYULH, third party) certified MBCT instructors  ....................................... 30 
11.3  INFORMED CONSENT PROCESS  .................................................................................................... 30 
11.3.1  Consent and Other Informational Documents Provided to Participants ................................ 30 
11.3.2  Consent Procedures and Documentation  ............................................................................. 30 
11.4  SUBJECT AND DATA CONFIDENTIALITY  .......................................................................................... 31 
11.4.1  Research Use of Stored Data  ............................................................................................... 31 
12 DATA HANDLING AND RECORD KEEPING  ................................................................................... 31 
12.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  .............................................................. 31 
12.2  STUDY RECORDS RETENTION  ....................................................................................................... 32 
12.3  PROTOCOL DEVIATIONS  ............................................................................................................... 32 
12.4  PUBLICATION AND DATA SHARING POLICY  ..................................................................................... 32  
13 STUDY FINANCES  ............................................................................................................................ 32  
13.1  FUNDING SOURCE  ........................................................................................................................ 32  
13.2  COSTS TO THE SUBJECT  ............................................................................................................... 33  
13.3  SUBJECT REIMBURSEMENTS OR PAYMENTS  .................................................................................. 33  
14 STUDY ADMINISTRATION ............................................................................................................... 33  
14.1  SITES .......................................................................................................................................... 33  
15 CONFLICT OF INTEREST  POLICY  .................................................................................................. 33  
16 REFERENCES  ................................................................................................................................... 34  
17 APPENDIX 1. SUICIDE SAFETY PLAN  ........................................................................................... 38  
 
  
Study number:  s20-01911   Page v 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authori zed 
in writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019   
List of Abbreviations  
 
AE Adverse Event/Adverse Experience  
EUC  Enhanced Usual Care  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
MBCT -T/V Telephone/video -delivered mindfulness -based cognitive therapy  
N Number (typically refe rs to participants)  
NIH National Institutes of Health  
NYULH  New York University Langone Health  
PI Principal Investigator  
RCT Randomized controlled trial  
SAE Serious Adverse Event/Serious Adverse Experience  
TEAM -M TrEAtment for Migraine and Mood  
US United States  
 
  
 
   
Study number:  s20-01911   Page 1 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  1 Key Roles  
 
Principal Investigator:    Amanda Shallcross, ND, MPH  
     NYU Langone Health  
Department of Population Health  
180 Madison Avenue, 7th Floor  
New York, NY 10016  
Amanda.Shallcross@nyulangone.org  
 
Co-Investigator:    Elizabeth Seng, PhD  
Yeshiva University  
Ferkauf Graduate School of Psychology  
1165 Morris Park Avenue, Rousso Building  
Bronx, NY 10461  
     Elizabeth.Seng@yu.edu   
 Co-Investigator:   Mia Minen, MD  
     NYU Langone Health  
Department of Neurology  
222 East 41st Street, 9th floor  
New York, NY 10017  
Mia.Minen@nyulangone.org  
 
Co-Investigator:   Rebecca Wells , MD , MPH  
     Atrium Health Wake Forest Baptist  
Department of Neurology  
Medical Center Boulevard 9th Floor  
Winston -Salem, NC 27157  
rewells@wakehealth.edu  
 
Co-Investigator:   Richard Lipton, MD  
     Albert Einstein College of Medicine  
1225 Morris Park Avenue  
Van Etten, Room 3C12C  
Bronx, NY 10461  
richard.lipton@einsteinmed.org  
     
 
Study Team Member:    Jacob Hill , ND, MS, FABNO  
     NYU Langone Health  
Department of Population Health  
180 Madison Avenue, 7th Floor  
New York, NY 10016  
Jacob.hill@nyulangone.org   
 Study Team Member:    Jodi Scharf, BA  
     NYU Langone Health  
Department of Population Health  
180 Madison Avenue, 7
th Floor  
New York, NY 10016  
Study number:  s20-01911   Page 2 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Jodi.scharf@nyulangone.org 
  
Study Team Member:    Barbara Ladenheim, PhD  
Albert Einstein College of Medicine  
1225 Morris Park Avenue  
Van Etten, Room 3C12C  
Bronx, NY 10461  
     barbaraladenheim@gmail.com  
 
Study Team Member:    Toby Dresdner  
Yeshiva University  
Ferkauf Graduate School of Psychology  
1165 Morris Park Avenue, Rousso Building  
Bronx, NY 10461  
tobydresdner96@gmail.com  
      
 
   
 
2 Introduction, Background Information and Scientific Rationale  
2.1 Background Information and Relevant Literature  
Migraine is a chronic condition with episodic attacks of head pain, nausea and/or vomiting, and/or sensitivity to 
light and sound. Migraine is  the world’s second leading cause of disability because of its high prevalence and 
negative impact on social and occupational functioning during a person’s peak years of productivity.  
A staggering 60% of people with migraine report some elevation of depressive symptoms, with 40% reporting an inability to feel pleasure. Depressive symptoms are associated with higher migraine disability (e.g., days missed of work and/or social activities), increased use of potentially harmful opioid therapies, and twice the t otal 
annual medical costs. Migraine and depressive symptoms have shared pathophysiological and neurobiological pathways and overlapping genetic profiles. Despite the significant emotional, social, and economic burden of 
this comorbidity, no existing treatment adequately addresses both migraine disability and elevated depressive 
symptoms. Development of scalable integrative treatments that address migraine disability and comorbid depressive symptoms has been identified as a major gap in migraine treatment.  
Mindfulness -based cognitive therapy (MBCT) is an evidence- based, standardized treatment comprised of 8 
weekly in- person classes and home practice. MBCT effectively addresses pain and depressive symptoms for 
a range of chronic pain conditions. Our preliminary data demonstrated that individual MBCT sessions reduced 
headache disability and depressive symptoms compared to treatment as usual in people with migraine. During 
exit interviews, participants noted that treatment delivery (in- person) and length (1.5- 2.5 hour-sessions) were 
barriers to accessing care. Remote and abbreviated delivery can address these barriers.   
2.2 Rationale  
Preliminary data demonstrated that an abbreviated (1hr/week) 8- week group- based telephone- delivered MBCT 
protocol (“MBCT -T”) is feasibl e and reduced depressive symptoms in people with hypertension. This MBCT -T 
protocol did not involve video- conferencing, which could enhance patient engagement and therapeutic benefit. 
However, the feasibility and acceptability of a video- conferenced- based protocol (MBCT -V) is unknown and has 
not been compared to MBCT -T. It is also unknown whether either abbreviated and remote- delivered versions 
of MBCT reduce depressive symptoms in patients with migraine.  
Study number:  s20-01911   Page 3 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  2.3 Potential Risks & Benefits 
2.3.1  Known Potential Risks  
 
General Risks Associated with Study Participation.  Participants in this study will have elevated depressive 
symptoms and may experience symptomatic exacerbation. All participants struggling with mood or suicidality will be counseled and referred by staff to all appropriate treatment modalities, including supportive treatment 
with additional psychotherapy or medications or immediate referral to psychiatric services available at local 
hospitals.   
 
Remote -delivered MBCT.  The physical risks of this intervention are minimal as no invasive procedures are 
involved. As participants will be a member of group sessions with other participants, there is a potential risk of 
a violation of privacy. Participants may experience escalating and/or destabilizing negative emotio nal 
experiences while practicing meditation. Also, symptomatic deterioration or the lack of response to treatment are possible risks of any clinical trial. Participants may experience emotional distress during the study given that participants have elevated depressive symptoms and engaging with and discussing negative emotions is part of the MBCT -T/V interventions. If a participant reports severe depressive symptoms or suicidal ideation at 
any time (e.g., during a study visit or during the intervention, eit her verbally or on the self -report depression 
inventory), the research coordinator/assistant or intervention facilitator will follow a detailed safety plan, which 
includes formal assessment of symptoms and, depending on the severity, providing referrals, informing the 
treating physician, arranging emergency care, and reporting the event to the IRB. Also, anxiety, dissociation, and depersonalization will be assessed over the course of the study as a part of our safety tracking to ensure monitoring of potential adverse reactions to MBCT -T/V. Participants with major  depressi ve disorder  will be 
excluded from our study at baseline. Please see Protections Against Risk for the detailed safety plan.  
 
Enhanced Usual Care (EUC) . EUC participants in this trial will be followed similarly to randomized participants 
but will not receive active psychological intervention from the study. Participants will receive educational 
information for migraine management and depression risk reduction and referrals to mental health resources. This will be in the form of 8 weekly online education modules whose content is based on education control groups used in previous behavioral migraine and depression research as described above.  
 
Alternative Procedures . MBCT has been shown to improve pain and depression outcomes. Other forms of 
psycho- education, therapy, and/or medications may be used in routine clinical care for adjunctive treatment. 
Study participants may thus be treated with these modalities outside of the study. Risks of these modalities are 
likely to be very similar to those of the study treatments. We have selected MBCT as the primary study intervention because it has been shown to improve pain and reduce depressive symptoms in a range of patient 
samples and is likely to provide benefits to study participants. Remote- delivered MBCT has not been well -
studied in patients with migraine and evidence is needed to determine its utility.  
2.3.2  Known Potential Benefits 
 Participants in this study might  benefit in a number of potential ways:  
 
• All participants will receive information about strategies to improve migraine management and 
depressive symptoms. Individuals may additionally benefit from the social connections created by the group format.  
 
• Beyond these direct benefits, participants may  also benefit from knowing that the information gained 
from this study will be an important step in developing new treatment options for treating people with migraine and depression, and thus, may have a large impact on the health and quality of life of many individuals.  
 
Taken together, these anticipated benefits outweigh the minimal risks to participants.  
Importance of the Knowledge to be Gained  
Study number:  s20-01911   Page 4 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  People with migraine have a high prevalence of depressive symptoms, yet accessible and scalable 
interventions are lacking. To our knowledge this is the first study to optimize two remotely  delivered  
mindfulness -based cognitive therapy interventions (MBCT -T and MBCT -V) to reduce suffering among patients 
with migraine and with depressi ve symptoms. This research proposal is poised to establish strong cross -
disciplinary collaborations with key experts in migraine and MBCT and will collect valuable data in preparation 
for the Phase III clinical trial of remotely -delivered MBCT.  
 
3 Objectives and Purpose  
 Aim 1. Conduct a 3-arm, multi- site pilot RCT of MBCT -T, MBCT -V, and EUC   
We propose a pilot three -arm, multi -site randomized controlled trial (n=144) of MBCT -T, MBCT -V, and 
Enhanced Usual Care (EUC) in people with migraine (defined by the International Classification of Headache Disorders – 3) and depressive symptoms (defined by empirical cut -offs on the Patient Health Questionnaire – 
9). Quantitative and qualitative feedback from patients and facilitators will be used to optimize both MBCT -T 
and MBCT -V treatment quality (e.g., patient comprehension) and delivery via iterative adaption and 
development of treatment manuals, facilitator training protocols, and fidelity measures [MBCT -T/V Adherence 
& Competence Scales (MBCT -TACS) and Session Fidelity Checklists].  
A. Demonstrate fidelity to MBCT -T
  and MBCT -V protocols across sites.  
Hypothesis (H)1: MBCT -T and MBCT -V sessions (n = 96 sessions) will be administered faithfully [MBCT -TACS 
scores ≥ 2.5] across treatment arm (MBCT -T vs. MBCT -V) and site (n = 3).  
B. Demonstrate feasibility and acceptability of MBCT -T , MBCT -V, and EUC.  
H1: MBCT -T, MBCT -V, and EUC will be feasible (Primary Outcome: 75% Session Attendance) and acceptable 
(Primary Outcome: Client Satisfaction Questionnaire- 8 (CSQ -8) score > 24) at each site.  
C. Demonstrate feasibility of study procedures.  
H1: Recruitment rate (Primary Outcome) will be ≥ 40% at each site.  
H2: Retention rate (Primary Outcome) will be ≥ 7 5% at each site and in each arm.   
Aim 2. Use decision rules to determine design for future fully -powered Phase III trial.  
Pre-specified decision rules for fidelity, feasibility, acceptability, and clinical utility will determine the arms of the 
future Phase III trial evaluating remotely -delive red MBCT for migraine disability and depressive symptoms.  
4 Study Design and Endpoints  
4.1 Description of Study Design  
This proposal aims to set the stage for a future definitive large- scale Phase III trial in patients with migraine and 
depressive symptoms. For this study, we propose a pilot three- arm, multi -site randomized controlled trial 
(n=144) of MBCT -T, MBCT -V, and Enhanced Usual Care (EUC) in people with migraine (defined by the 
International Classification of Headache Disorders – 3) and depressive symptoms (defined by empirical cut -offs 
on the Patient Health Questionnaire – 9). 
 
Study number:  s20-01911   Page 5 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  5 Study Enrollment  and Withdrawal 
5.1 Inclusion Criteria  
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
 
• Currently meets ICH D-3 criteria for migraine using the American Migraine Prevalence and Prevention 
Diagnostic Module  
• Self-reported 4- 14 headache days per month, with at least one attack meeting migraine criteria  
• Score between 5- 14 on the PHQ -9 
• Age ≥ 18  
• Ability to read and speak English  
• Capacity to consent  
• Prospective diary -confirmed 4- 14 headache days per month, with at least one attack meeting 
migraine criteria  
• ≥1 year of migraine  
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
 
• Meeting ICHD -3 criteria for persistent headache attributed to traumatic injury to the head (post -
traumatic headache) on the American Migraine Prevalence and Prevention Diagnostic Module  
• Changes in preventive migraine medication or anti -depressant medication within 6 weeks of intake 
• Changes in longer -term migraine prevention (onobotulinum toxin A, injectable or oral anti- calcitonin 
gene related peptide treatment; neuromodulatory device) within 3 months of intake 
• Changes  in acute migraine treatment started within 4 weeks of enrollment  
• Comorbid psychiatric illness or clinical features that would interfere with participant’s ability to 
participate in or receive benefit from the MBCT -T intervention, including but not limited to: active suicidal 
ideation; recent history of psychosis or mania; borderline, histrionic or narcissistic personality disorder; cognitive impairment; sensory disabilities; bipolar disorder; obsessive- compulsive disorder, drug use  
• Prior history of engaging in formal mindfulness -based interventions including: MBSR, MBCT, 
Acceptance and Commitment therapy, Dialectical Behavior Therapy  
• Current daily meditation practice  
• Inability to adhere to headache diary during baseline evaluation period (recorded fewer than 25/28 days)  
• Unwilling to maintain stable current acute or preventive medication dosages for study duration  
• Any condition that would prevent being a suitable candidate or interfere with medical care needs  
• Inability to adhere to headache diary during baseline evaluation period (recorded fewer than 25/28 days).  
 
5.3 Vulnerable Subjects  
No vulnerable populations will be studied.  
 
5.4 Strategies for Recruitment and Retention  
Two main recruitment methods will be used to identify potentially eligible participants:  
5.4.1  Referrals from Clinician Co-Investigator  and NYU -Affiliated Specialist  
Co-Investigator s Lipton, Minen, and Wells  see patients in their  own neurology practices . When a Co-I identifies 
a potentially eligible subject  during an office visit, he/she will inform  them of the research study  and provide 
them with an IRB -approved study brochure . Patients who are interested in participating will provide their 
permission for the Co- Is to notify the study team and grant permission to directly contact the potential subject 
on their behalf.  
Study number:  s20-01911   Page 6 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019   
The study team will also receive referrals from Dr. Audrey Halpern, NYU -affiliated headache specialist. Dr. 
Halpern has referred participants to Dr. Minen’s NYU IRB -approved studies in the past. Her contact details 
are as follows:  
 Dr. Audrey Halpern  
Clinical Assistant Professor, Department of Neurology at NYU Grossman School of Medicine  
(646) 559- 4659  
drhalpern@audreyhalpernmd.com  
108 West 39th S treet, Suite 405, Fourth floor  
New York , NY 10018  
 When Dr. Halpern identifies a potentially eligible subject  during an office visit, she will inform them of the 
research study  and give them the IRB- approved study brochure. Patients who are interested in participating 
will provide their permission for Dr.  Halpern to notify the study team and grant permission to directly contact 
the potential subject on her behalf.  
5.4.2  Use of DataCore/ EPIC Information  for Recruitment Purposes  
This study  will also utilize electronic health records (EHR) to enhance recruitment. Study team will submit an 
online request in accordance with institutional protocols  (Ex. DataCore at NYU, CLG and/or Atlas at Montefiore) 
at each site institutions to identify a list of patients with an ICD -10 diagnosis of headache seen in general 
neurolog y and primary care clinics affiliated with NYULH in the last 6 mont hs.  
 At this point, the study team will reach out to prospective participants via an IRB- approved recruitment message 
communicating the reason they are being contacted. Interested participants will be invited to determine their preliminary eligibility by clicking on a REDCap- hosted link containing a study pre- screener. Potential subjects 
who are active in MyChart will be contacted via MyChart. Potential subjects who are not active in MyChar t will 
be sent a [SAFE] email message containing the IRB -approved recruitment message.  
 If individuals request information regarding opting out of further recruitment for all research, they will be 
directed to research- contact -optout@nyulangone.org or 1-8 55-777-7858, or the equivalent opt -out 
procedures/contact at each study site.  
Online pre- screening via REDCap will determine preliminary eligibility based on inclusion/exclusion criteria 
including the following (see Sections 5.1 and 5.2 for details):  
 
• Dem ographic information  
• Ability to consent  
• Mindfulness experience  
• Migraine symptoms  
• Depression and other psychiatric symptoms  
• Interest in the study  
 
Participants will be directed to an online screening survey with a waiver of signed consent to assess eligibility; a phone call can be requested (if low literacy or low technology use). A cover letter will be included with the 
online screen that will serve as study introduction and include some consent information (due to low risk, it is 
not required to be signed).  Participants will be asked if they are interested in future research. Contact 
information for individuals interested in future studies will be retained in a separate REDCap  file that will not 
be linked to any data from the pre- screener. Individua ls will be contacted after the REDCap pre- screening 
questionnaire to inform them of their eligibility status. Those who are preliminarily eligible will continue on to the screening phone call for further eligibility evaluation for inclusion into the study.   
 
Study number:  s20-01911   Page 7 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  5.5 Duration of S ubject  Participation  
Each subject will be involved in the study for  10-11 months , including up to 2 weeks of consent and screening 
procedures, a 1-month run- in period, baseline/M0 assessments, the 8- week intervention, and assessments at 
mid-intervention/M1, post-intervention/M2, and follow -ups M3, M6, and M9. 
 
5.6 Total Number of Subjects  and Sites  
N = 144 people with migraine and mild- moderate depressive symptoms will be recruited from: NYULH (n = 48), 
Montefiore Health System  (n = 48) and Atrium Health Wake Forest Baptist  (n  = 48). The n=144 will allow each 
site to have 2 groups within each treatment arm; for example, at the NYULH site, the total n = 48: MBCT -T (2 
groups, n = 16), MBCT -V (2 groups, n = 16) and EUC (2 groups, n = 16).  
5.7 Subject Withdrawal or Termination  
5.7.1  Reasons for Withdrawal or Termination  
Subjects  are free to withdraw from participation in the study at any time upon request. An investigator may 
terminate participation in the study if:  
 
• Any clinical adverse event (AE)  or other medical condition or situation occurs such that continued 
participation in the study would not be in the best interest of the participant  
• The participant meets an exclusion criterion (either newly developed or not previously recognized) that 
preclud es further study participation  
 
5.7.2  Premature Termination or Suspension of Study 
 This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or termination, will be provided by the suspending or terminating party to the investigator, funding agency, and regulatory authorities. If the study is 
prematurely terminated or suspended, the PI will promptly inform the IRB and will provide the reason(s) for the 
termination or suspension.  
 Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stopping  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
• Determination of futility  
• Any condition that would prevent being a suitable candidate or interfere with medical care needs  
 Study may resume once concerns about safety, protocol compliance, data quality are addressed and satisfy 
the sponsor and/or IRB.  
 
6 Psychological Intervention 
6.1 Intervention Description 
 Mindfulness -based cognitive therapy (MBCT) is an evidence- based, standardized treatment comprised of 8 
weekly classes and home practice. MBCT effectively addresses pain and depressive symptoms for a range of chronic pain conditions.  
Study number:  s20-01911   Page 8 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  6.1.1  Administration of Intervention 
 
To maintain clinical equipoise, an independent MBCT instructor will administer the remote- delivered MBCT -T 
and MBCT -V sessions . We will contract clinical psychologist s (master’s level or above)  to teach MBCT  who will 
be supervised by a certified MBCT instructor . Both MBCT -T and MBCT -V will be remote- delivered using NYULH 
WebEx conferencing, which allows for a ‘call -in’ option that does not require internet . 
6.1.2  Make- Up Session Protocol  
 Participants who are unable to attend a session will be able to listen to the audio of the study session via a 
secure recording. The participant will schedule a time for the make- up and will receive a personalized REDCap 
link and will be required to input their study ID before proceeding to the next page. If they fail to input the correct study ID, the REDCap  survey will end. The next screen of the REDCap survey wi ll contain an embedded audio 
recording of the study session. The recording will only be available for a short window and the REDCap  survey 
link will expire 2 hours after the participants have scheduled to listen to the make- up session. During the calls, 
participants are told to not state more than their first names and if a participant does add any additional 
information, the audio file will be edited to remove that information. The audio will be hosted through a private 
Soundcloud file that cannot be downloaded and is not publicly visible, and sessions will be deleted from the platform as soon as the make- up is completed.  
6.1.3  Procedures for Training Interventionalists and Monitoring Intervention Fidelity  
 In accordance with recommendations in the field, the clinician  will be required to have a minimum of master’s 
level training in clinical psychology and a regular mindfulness practice of at least two years. The clinician  will 
be licensed or will be practicing under a licensed clinician. Fidelity will be ensur ed by using treatment manuals, 
session fidelity checklists, and weekly supervision of session audio recordings to minimize drift. Treatment 
fidelity will be evaluated by two or more independent raters, with a minimum of 85% inter -rater reliability, using 
the MBCT -TACS scale.  
6.1.4  Assessment of Subject Compliance with Study Intervention 
 
Treatment Session Adherence is a measure of treatment feasibility. This measure will be assessed through electronic monitoring of the attendance logs of each treatment session. The number of MBCT -T/V treatment 
sessions attended will be recorded. A treatment arm will be considered feasible if participants attended/read 75% of sessions on average.  
 
Homework assignment adherence is a nother  measure of treatment feasibility. During the  intervention period, 
participants in the MBCT groups will be asked to record the amount of assigned home- based practice they 
completed each week  via REDCap Mobile or Gene Doe app.  
 
The Gene Doe app, in addition to REDCap Mobile, will be used to administer  the daily headache diary as well 
as monitor homework adherence during the baseline run- in period through the intervention and during the post -
treatment evaluation period. Gene Doe is a mobile phone research platform that interfaces with REDCap for 
secure capture of patient -reported outcomes. The Gene Doe app data collection and functionality was  reviewed 
by Russ Raymond, Patrocinio Domingo, and Rick Church at NYU -MCIT who determined this app does not 
require full MCIT security review and have cleared Gene Doe for use in this study.  
 
Study number:  s20-01911   Page 9 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  7 Study Schedule and Procedures  
7.1 Study Schedule  
 
7.1.1  Pre-screening (online)  
• Expected to take between 15- 25 minutes  
• Obtain pre- screener consent via REDCap  
• Online screening questionnaires  
7.1.2  Further Eligibility Screening (phone)  
• Expected to take between 20- 40 minutes within 2 weeks of pre- screener  
• Obtain e- Consent via REDCap  
• Further eligibility screening (verbal)   
7.1.3  28-Day Baseline Run -In 
• Daily diary including headache symptoms  
• 28-day period  to ensure inclusion/exclusion criteria for: 
o Migraine diagnosis  
o Minimal diary adherence (25/28 days ) 
7.1.4  Intervention Assignment & Intervention Orientation  
• PI confirms final eligibility  
• Participant is randomized to MBCT -T, MBCT -V, or EUC  
• If randomized to MBCT -T or V, p articipant will be scheduled for a 30- minute orientation with the 
facilitator of the intervention  
7.1.5  Baseline/M0  
• Expected to be completed in 30- 45 minutes within 5 days of the start of the intervention  
• Surveys via REDCap (see section 7.2.1.5 and 7.2.1.6 for details)  
7.1.6  Study Intervention  
• Will beg in once 6- 8 participants are assigned to intervention  

Study number:  s20-01911   Page 10 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  • Administered over 8 weeks (see section 6 for details)  
7.1.7  Mid-intervention/M1  
• Expected to be completed in 15 minutes halfway through the intervention  
• Surveys via REDCap (see section 7.2.1.5 and 7.2.1.6 for details)  
7.1.8  Post -intervention/M2  
• Expected to be completed in 30- 45 minutes, within two weeks of intervention completion  
• Surveys via REDCap (see section 7.2.1.5 and 7.2.1.6 for details)  
• A sub -sample of  participants  with varying levels of engagement with the study  (approximately 3- 4 from 
each cohort) will be invited to provide post -intervention individual qualitative feedback about the 
feasibility and acceptability of the study procedures and intervention  
7.1.9  M3 
• Expected to be completed in 30- 45 minutes, within +/- 2-week of 3 months since baseline  
• Surveys via REDCap (see section 7.2.1.5 and 7.2.1.6 for details)  
• A sub -sample of  participants  with varying levels of engagement with the study  (approximately 3- 4 from 
each cohort) will be invited to provide post -intervention individual qualitative feedback about the 
feasibility and acceptability of the study procedures and intervention  
 
7.1.10  M6 
• Expected to be completed in 30- 45 minutes, within +/ -2-week of 6 months since baseline  
• Surveys via REDCap  (see section 7.2.1.5 and 7.2.1.6 for details)  
• A sub -sample of  participants  with varying levels of engagement with the study  (approximately 3- 4 from 
each cohort) will be invited to provide post -intervention individual qualitative feedback about the 
feasibi lity and acceptability of the study procedures and intervention  
7.1.11  M9 
• Expected to be completed in 30- 45 minutes, within +/ - 2-week of 9 months since baseline  
• Surveys via REDCap (see section 7.2.1.5 and 7.2.1.6 for details)  
• A sub -sample of  participants  with va rying levels of engagement with the study  (approximately 3- 4 from 
each cohort) will be invited to provide post -intervention individual qualitative feedback about the 
feasibility and acceptability of the study procedures and intervention  
 
7.2 Study Procedures and Evaluations  
7.2.1  Study Specific Procedures   
7.2.1.1  Further Eligibility Screening    
 
Individuals who meet pre- screening eligibility and who are interested in taking part in this study will be provided 
with e -Consent materials (hosted on REDCap) and will be  scheduled to meet with a Research Assistant via 
telephone or video to review e-Consent materials, answer questions, and confirm understanding of the study 
procedures. If still interested, the subject will electronically sign the e- Consent and a pdf copy w ill be provided 
to them.  
 Individuals who meet preliminary eligibility criteria and who consent to participation in this study will stay on the call for further eligibility screening (20- 40 minutes). During this eligibility interview, study staff will:  
 
Study number:  s20-01911   Page 11 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  • Conduct a structured interview and then review responses with the study neurologist  at each site to 
ascertain whether the subject meets ICHD- 3 criteria for migraine using the American Migraine 
Prevalence and Prevention Diagnostic Module  
• Administer the PHQ -9 to assess depression and suicidality  
• Ask additional  eligibility questions as outlined in the “Phone Screener” document  
 
Drs. Shallcross, Seng,  Lipton,  Minen, and Wells  will provide supervision at their respective sites on depression 
and migraine inclusion/exclusion criteria and will be available to address any questions regarding these criteria.  
 Subjects  who pass this eligibility assessment will be assigned to an intervention  and scheduled for a 30- minute 
individual orientation session with the intervention facilitator . 
 
28-Day Baseline Run -In 
 
Participants who meet preliminary criteria and provide informed consent will complete a 28- day baseline run- in 
to ensure participants meet inclusion/exclusion criteria for migraine diagnosis and the threshold for minimal diary adherence (25/28 days). During the baseline run- in, participants will complete a daily diary including 
headache symptoms using the REDCap Mobile App  or Gene Doe app. If participants do not have a personal 
device, one will be provided by the research team. The application will prompt a diary entry at a time selected 
by the participant each evening. If a patient does not submit a daily entry, they  will be alerted that the diary 
entry is still waiting for 12 hours. Participants will not be permitted to record retrospective data to reduc e recall 
bias. Participants who continue to meet inclusion/exclusion criteria after the 28- day baseline run- in will be 
randomized to receive either 8 sessions of MBCT -T, MBCT -V, or Enhanced Usual Care.  
7.2.1.2  Randomization 
Randomization will be stratified by headache days [low -frequency episodic migraine (4- 9 days/28 days), high-
frequency episodic migraine (10- 14 days/28 days)] and gender (male, female). A randomization list will be 
generated by the study statistician using randomization within random blocks of sizes 3 and 6. Participants will 
be masked to intervention options and study hypotheses. They will be informed that they will be randomized to 
one of three interventions that will last a maximum of 8 weeks and that will provide knowledge to help migraine and depressive symptoms. Facilitators will be unmasked. Data will be entered and coded so that group 
membership is known only to the project coordinator at NYULH and to research assistants who are coordinating 
study visits. The graduate research assistant who will be coordinating data capture across sites, as well as the investigators, will be masked to treatment condition.  
 
7.2.1.3  8-Week Intervent ion Program 
7.2.1.3.1  MBCT -T/V 
Both MBCT -T and MBCT -V will be delivered using WebEx conferencing, which allows for a ‘call -in’ option that 
does not require internet for the MBCT -T arm. MBCT -T/V will be delivered to groups of 8 migraine patients in 8 
weekly, 1- hour s essions.  Smartphone devices with u nlimited data plans will be  available for participants who 
need them to participate in the study both to complete the headache diary (see below for details) and if they are randomized to either remote- delivered intervention. Our team has used the WebEx platform for three clinical 
trials and will ensure that all facilitators and research support staff are trained and that a comprehensive manual is available to help troubleshoot potential technical difficulties. At least one research assistant will join each weekly session to help assist with any technical difficulties participants may have. Unforeseen difficulties with 
the technology will provide us with additional information about the feasibility of this intervention.  
Critical components of MBCT include: 1) learning mindfulness skills; 2) practicing mindfulness skills in class and at home; and 3) dialogue and inquiry. The intervention manual will be an adapted version of Dr. Shallcross’ remote- delivered MBCT for chronic pain  protocol (i19- 00339) and Dr. Seng’s in- person MBCT for migraine 
Study number:  s20-01911   Page 12 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  protocol. All sessions will be audio- recorded. Patients will be encouraged to practice daily meditation in between 
group sessions for 20 minutes, 6 days per week.  
As a headache diary is a core component of all headache treatments, participants will complete a daily 
headache diary, which will include recording of daily meditation practice. To maximize adherence and retention, coordinators will give reminder calls to patients prior to each weekly class and will contact patients who miss a weekly session to schedule a make- up session, whereby patients can listen to the audio recording of the missed 
session.   
 
 
7.2.1.3.2  EUC 
Participants randomized to EUC will receive usual care and 8 weekly online education modules whose delivery and content are based on control groups from previous behavioral migraine and depression interventions. Modules will be released on a weekly basis, which mirrors the MBCT arms. Participant engagement with each  

Study number:  s20-01911   Page 13 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  module happens individually (not in a group) and will be tracked electronically by the secure hosting website. 
Participants will also complete a daily headache diary.  
 
 
7.2.1.4  Assessments  
 
Please see Table 3 for an overview of assessment timeline and sections 7.2.1. 6 and 7.2.1. 7 for details.  
 
Subjects  will be asked to complete questionnaires  online via REDCap , via REDCap Mobile App, or via Gene 
Doe App,  (or on paper if they prefer – we will mail subjects  the questionnaires).  
 
Table 3. Schedule of Assessments  
 Data collection by study personnel  Assessments completed by participants  
Pre-Screening   Online Pre -screener  
Screening  Recruitment Rate  
Daily Diary Completeness  Phone Screener  
Headache frequency  
M-1^   Demographics  
FFMQ -15 
HMSES  
CEQ  
QIDS  
PROMIS  
Off-Protocol Co-Occurring Treatment Tracking  
HDI 
MSQ  
Survey Acceptability Questionnaires -7 
Daily Diary  
(M-1 - M3)  Headache frequency  
Average Headache Attack Pain Intensity  
M0* Survey Completeness  
Daily Diary Completeness  SUS-Data Capture  
HDI 
QIDS  
PROMIS -D 
MSQ  

Study number:  s20-01911   Page 14 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  HMSES  
MAIA -2 
PCS 
HPAQ 
MIDAS  
Weekly During 
Intervention  Treatment Session Adherence  
Fidelity Checklist  
Survey Completeness  Safety Tracking  
Homework Assignment Adherence  
M1**  Survey Completeness  
Daily Diary Completeness  
Attrition  QIDS  
PROMIS -D 
HDI 
MSQ  
MBCT -HPI 
MAIA -2 
PCS 
HPAQ 
MIDAS  
Survey Acceptability Questionnaires -7 
M2*** MBCT -TACS  
Survey Completeness  
Retention Rate  
Survey Completeness  
Daily Diary Completeness  
Attrition  CSQ -8 
FFMQ -15 
HMSES  
SUS-Treatment  
QIDS  
PROMIS -D 
Off-Protocol Co-Occurring Treatment Tracking  
HDI 
MSQ  
MBCT -HPI 
MAIA -2 
PCS 
HPAQ MIDAS  
For some: M2 Qualitative Questions  (Exit 
interview)  
M3° Survey Completeness  
Daily Diary Completeness  
Attrition  CSQ -8 
MBCT -HPI 
SUS-Data Capture  
HDI 
QIDS  
PROMIS -D 
MSQ  
MAIA -2 
PCS 
HPAQ 
MIDAS  
Survey Acceptability Questionnaires -7 
M6°° Survey Completeness  
Attrition  CSQ -8 
MBCT -HPI 
SUS-Data Capture  
HDI 
QIDS  
PROMIS -D 
MSQ  
MAIA -2 
PCS 
HPAQ 
MIDAS  
M9°°° Survey Completeness  
Attrition  CSQ -8 
MBCT -HPI 
HDI 
QIDS  
PROMIS -D 
Study number:  s20-01911   Page 15 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  MSQ  
MAIA -2 
PCS 
HPAQ 
MIDAS  
As Needed   BSS 
^ M-1 = Month -1/Baseline; * M0 = Month 0/Pre-Intervention ; ** M1 = Month 1/Mid-Intervention; ***  M2 = Month 2/Post-
Intervention; ° M3 = Month 3 (1 Month Post -Intervention) ; °° M6 = Month 6 (4 Months Post -Intervention) ; °°° M9 = Month 9 
(7 Months Post -Intervention)  
 
7.2.1.5  Details of Participant Assessments  
Name:   O nline pre- screener  
Type :   Other  
Time Frame :  Pre-screening (online)  
Brief Description : The online pre- screener assesses preliminary inclusion and exclusion criteria. See 
sections 5.1 and 5.2 as well as the attached document “PRE -SCREENER” for details.  
 
Name:     Phone Screener  
Type:     Other  
Time Frame:    Screening (verbally, post -e-Consent)  
Brief Description:   The Phone Screener  assesses inclusion  and exclusion  criteria  that are more 
nuanced than what is included in the pre- screener and require a member of the study 
team’s training and judgment . Questions will involve assessing depressive symptoms 
using the PHQ -9. Other questions involve assessing migraine symptoms, many  of 
which will be open- ended, including recent changes to headache symptoms , 
medications,  and recent hospitalizations.   
Name:     Migraine Symptoms Checklist  
Type:     Other  
Time Frame:    Screening (verbally, post -e-Consent)  
Brief Description:   The Migraine Symptoms Checklist assesses inclusion criteria. It is a brief structured 
interview to guide the formal diagnosis of migraine without aura using the current 
International Classification of Headache Disorders – 3 criteria.  The interview has 15 
items to assess migraine without aura.  
Name:     Pat ient Health Questionnaire – 9 (PHQ -9) 
Type:     Other  
Time Frame:    Screening (verbally, post -e-Consent)  
Brief Description:   The PHQ -9 assesses inclusion criteria. It is a self -reported measure of depressive 
symptom severity and consists of items consistent with criteria for DSM- based 
diagnosis. PHQ -9 scores range from 0 to 27. Each of the 9 items can be scored from 
0 (“not at all”) to 3 (“nearly every day”). Cut -points of 5, 10, 15, and 20 represent the 
thresholds for mild, moderate, moderately severe, and severe depression, 
respectively. The construct validity of the PHQ -9 has been demonstrated in a wide 
range of patient populations.  
Name:     Head ache Frequency  
Type:     Secondary  
Time Frame:   Headache activity is captured each day during the daily diary from Screening to M3. 
Brief Description:   Headache days/28 days . Each day participants will be asked, “Did you have a 
headache today?” with response options of “Yes,” and “No.” Each day on which a 
participant reports “Yes” will be coded as a headache day.  
Name:     Av erage Headache Attack Pain Intensity  
Type:     Secondary  
Study number:  s20-01911   Page 16 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Time Frame:   The measure is administered in the daily diary from Screening through Month 3 on 
days during which a headache was recorded.  
Brief Description:   On eac h day when a participant reports they had a headache, participants will be 
asked to rate their pain on a scale from 0- 10, with 0 indicating no pain, 1- 3 indicating 
mild pain, 4- 6 indicating moderate pain, and 7- 10 indicating severe pain.   
Name:     Dem ographics  
Type:     Other  
Time Frame:    M-1 
Brief Description:   Demographics will include age, sex, income, education, race, ethnicity, marital status, 
family structure, and occupation.  
Name:     Cl ient Satisfaction Questionnaire – 8 (CSQ -8)  
Type:     Primary  
Time Frame:    M2, M3, M6, M9  
Brief Description:   The CSQ -8 assesses treatment acceptability. The CSQ -8 is an 8- item self -report 
measure designed to assess satisfaction with mental health services. Response 
options are coded on a 4- point scale and summed to produce a total score ranging 
from 8 -32. The measure has consistently demonstrated excellent reliability and 
validity, and is commonly used in behavioral treatment trials. For the purposes of this study, we consider “acceptable” to be a CSQ -8 score > 24 at Month 2.  
Name:    Fi
 ve Facet of Mindfulness Sc ale (Short Form; FFMQ -15) 
Type:     Secondary  
Time Frame:   M0 and M2  
Brief Description:   The FFMQ is a measure of treatment fidelity. The FFMQ measures pre- post trait 
mindfulness and is assessed using 15 items that index the degree to which participants experience daily mindfulness, a central objective of the MBCT -T 
treatment. Each item is rated on a 5- point scale from ‘1’ = never or very rarely true to 
‘5’ = very often or always true. An example item is “When I take a shower or a bath, I stay alert to the sensations of water on my body.” Scores range from 15- 75, with 
higher scores reflecting greater trait mindfulness.  
Name:    Head
 ache Management Self -Efficacy Scale (HMSES)  
Type:     Secondary  
Time Frame:   M0 and M2  
Brief Description:   For the EUC group, we will assess self -efficacy for headache self -management skills 
using the Headache Management Self -Efficacy Scale (HMSES), which is a validated 
instrument widely used in migraine studies. The HMSES is a 25- item scale that 
assess confidence in one’s ability to successfully manage migraine using behavioral strategies. Each item is rated on a 7- point Likert scale ranging from ‘1’ = Strongly 
Disagree to ‘7’ = Strongly Agree. An example item is, “I can prevent headaches by changing how I respond to stress.” Scores range from 25- 175, with higher scores 
indicating higher self -efficacy.  
Name:    Mult
 idimensional Assessment of Interoceptive Awareness Version 2 ( MAIA-2) 
Type:     Secondary  
Time Frame:   M0, M1, M2, M3, M6, M9  
Brief Description:  The MAIA -2 is a 37- item questionnaire that will be used to assess body/somatic 
awareness and interoceptive awareness throughout the study. Body awareness is important when considering mindfulness -based interventions, which focus on 
nonjudgmental acceptance of body sensations and a sense of self -ground ing in 
physical sensations in the moment. This questionnaire will be important to monitor 
baseline body awareness and changes in body awareness as participants 
experience the intervention or control.  
Study number:  s20-01911   Page 17 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Name:    P ai n Catastrophizing Scale  (PCS)  
Type:     Secondary  
Time Frame:   M0, M1, M2, M3, M6, M9  
Brief Description:  The PCS will be used to monitor for pain catastrophizing throughout the study , which 
is the tendency to magnify the threat of a painful experience, feel helpless in the 
presence of pain, and be unable to prevent and inhibit pain- related thoughts . This is 
an important measure to monitor how participants experience their headache pain 
during the intervention or control.  
Name:    Head P ain Acceptance Questionnaire (HPAQ)  
Type:     Secondary  
Time Frame:   M0, M1, M2, M3, M6, M9  
Brief Description:  The HPAQ will be used to measure the level of acceptance participants have 
regarding their headache pain. Pain acceptance can have an important role in managing pain disorders and is generally considered to facilitate positive health 
outcomes.  Head pain acceptance will be monitored throughout the study.  
Name:     Cr
 edibility/Expectancy Questionnaire (CEQ)  
Type:     Secondary  
Time Frame:    M0 
Brief Description:   The CEQ is a measure of treatment acceptability. The CEQ is a 6- item measure with 
two subscales: credibility and expectancy. Four of the 6 items are rated on a 9- point 
scale, and two items are rated from 0- 100%. Items are standardized and a composite 
is formed for each subscale, with higher scores indicating higher credibility and 
expectancy.  
Name:     Qui ck Inventory of Depressive Symptomatology – Self-Report 16 (QIDS -SR 16) 
Type:     Secondary  
Time Frame:    M0, M1, M2, M3, M6, M9  
Brief Description:   The QIDS -SR 16 measures depressive symptom domains during the prior 7 days. 
Each item is scored on a scale from 0 to 3 points. Total scores range from 0 to 27. Score cutoffs are: 1–5 for no depression, 6– 10 for mild depression, 11– 15 for 
moderate depression, 16– 20 for severe depression, and 17 –27 for very severe 
depression. The QIDS- 16 has been used widely in intervention studies and has 
sound psychometric properties, including strong internal consistency, concurrent validity, and sensitivity to symptom change.  The slope of change between Month 0 
and 3 represents the primary endpoint which will be used as the effect size for sample size estimation for the fully -powered trial.  
Name:     Pat
 ient Reported Measurement Information System – Depression (PROMIS -D) 
Type:     Secondary  
Time Frame:    M0, M1, M2, M3, M6, M9  
Brief Description:   The PROMIS -D measures depressive symptom domains during the prior 7 days. 
Each item is scored on a scale from 1 to 5 points. Scores are converted to t -scores 
based on normative data. The PROMIS- D is a commonly used measure of 
depressive symptoms and has demonstrated sound psychometric properties, 
including excellent internal consistency and concurrent validity.  The slope of change 
between Month 0 and 3 represents the primary endpoint which will be used as the 
effect size for sample size estimation for the fully -powered trial.  
Name:     Off-P rotocol Co- occurring Treatment Tracking 
Type:     Secondary  
Time Frame:    M0 and M2  
Brief Description:   This is an inventory in use in Dr. Shallcross’ lab that assesses any changes in the 
medications or other treatments the patient is using to manage their migraine, mental 
Study number:  s20-01911   Page 18 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  health, or any other medical symptoms. Changes to acute migraine medication, anti -
depressant medications, and psychotherapy will be specifically tracked in those 
categories.    
Name:     Headache Disability Inventory (HDI)  
Type:     Secondary  
Time Frame:   M0, M1, M2, M3, M6, M9  
Brief Description:   The HDI is a 25- item self -report survey which assesses perceived emotional and 
functional impact of headache on daily activities. Sample items include, “Because of 
my headaches I feel restricted in performing my routine daily activities,” with 
response options of “Yes,” “Sometimes,” and “No.” Total scores range from 0- 100, 
with higher scores indicating higher disability. The HDI has demonstrated excellent internal consistency and test -retest reliability in people with migraine. The slope of 
change between Month 0 and 3 represents the primary endpoint w hich will be used 
as the effect size for sample size estimation for the fully -powered trial.  
Name:     Mig
 raine -Specific Quality of Life Questionnaire v 2.1 (MSQ)  
Type:     Secondary  
Time Frame:    M0, M1, M2, M3, M6, M9  
Brief Description:   The MSQ is a 14- item self -report survey which assesses quality of life over the past 4 
weeks in people with migraine. Items comprise three subscales: Role Restriction, Role Prevention, and Emotion Function. Each item is scored on a Likert -type scale 
from 1  (“None of the time”) to 6 (“All of the time”).   Total scores range from 14- 84. 
The slope of change between Month 0 and 3 represents the primary endpoint which will be used as the effect size for sample size estimation for the fully -powered trial.  
Name:     MID
 AS 
Type:     Secondary  
Time Frame:    M0, M1, M2, M3, M6, M9  
Brief Description:   The Migraine Disability Assessment (MIDAS) questionnaire is a 5-item, self -
administered questionnaire designed to quantify headache- related disability . It 
includes five questions regarding days of activity limitations in work, chores (household work), and non- work activities (social, family and leisure activities), to 
score the level of disability from headaches.  Total scores reflect the number of days 
of disability and range from 0- 22+ days , with over 22 days indexing severe disability.  
Name:     MBC
 T Home Practice Inventory (MBCT -HPI) 
Type:     Secondary  
Time Frame:    M1, M2, M3, M6, M9 (MBCT groups only)  
Brief Description:   The MBCT -HPI is a measure of treatment feasibility.  The MBCT -HPI is a log (in 
calendar form) that individuals use to record the amount of daily formal and informal 
practice (# of times and minutes of practice) of mindfulness meditation that they have 
completed over the past month. In addition to time practicing, participants can complete a notes section to elaborate on their experience.  
Name:     Sy
 stem Usability Scale (SUS): Treatment   
Type:     Secondary  
Time Frame:    M2 
Brief Description:   The SUS for Treatment is a measure of treatment acceptability. The SUS is a 10 -item 
scale that assesses end- user perceived usability of information technology systems. 
For the current scale, the system being evaluated will be the WebEx system for treatment delivery for both the MBCT -T (no internet connection required) and MBCT -
V arms of the study, and the online education platform used for the EUC arm of the 
study. Response options range from 1- 5; half of the items are positively worded, and 
Study number:  s20-01911   Page 19 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  half are negatively worded. Scores are converted to a score ranging from 0- 100 wit h 
higher scores indicating higher perceived usability.  
Name:     System Usability Scale (SUS): Data Capture  
Type:     Secondary  
Time Frame:    M3, M6  
Brief Description:   The SUS for Data Capture is a measure of acceptability of study procedures. The 
SUS is a 10- item scale that assesses end- user perceived usability of information 
technology systems. For the current scale, the system being evaluated will be the 
mobile application used for data capture for surveys and daily diary. Response 
options range from 1- 5; half of the items are positively worded, and half are 
negatively worded. Scores are converted to a score ranging from 0- 100 with higher 
scores indicating higher perceived usability.   
Name:     Bec k Suicide Scale (BSS)  
Type:     Secondary  
Time Frame:   As needed - t he measure is administered any  time an individual indicates a presence 
of suicidal thoughts on either the PHQ -9 or the QIDS -16 or in between assessments 
to anyone on the study team.    
Brief Description:   Thi s is a standard 21- item scale that members of the research team have used in pr ior 
trials to assess risk of suicide. The BSS indexes current intensity of attitudes, plans, and behaviors to complete suicide. Scores over 11 and/or endorsement of a ‘2’ on any 
of the following items 12, 15, 16, 18, and 21 indicate notable risk. See Appendix 1  for 
suicide safety protocol.  
 
Name:  
   Safety Tracking 
Type:     Secondary  
Time Frame:   Intervention. The measure is administered via survey and RA check -ins by telephone 
(mid-way through the intervention period) at Months 1 and 2. Total number of 
Adverse Events (AEs) and Serious Adverse Events (SAEs) will be evaluated.  
Brief Description:   AE a n d SAE data  will be collected through s urvey s and by RAs. Surveys include 
standardized inventories that measure anticipated adverse events, including anxiety, 
flooding, depersonalization, and dissociation, as well as an open- ended question 
about any other troublesome medical occurrences. RA check -ins (mid -way through 
the intervention period) will involve inquiry about migraine and depressive symptom deterioration and suicidal ideation. An adverse event (AE) is any troublesome medical occurrence in a subject during participation in the clinical study. A serious adverse event (SAE) is any AE that results in one or more of the following outcomes: death, a life- threatening event, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant disability/incapacity, a congenital anomaly or birth defect, or an important medical event based upon appropriate medical judgment. We will use the HHS/NIH/NCI Common Terminology Criteria for Adverse Events (Version 4.0) grading scale. The RA(s), neur ologist Co -I and PI will work 
together to determine AEs and SAEs.  
Name:     Hom
 ework Assignment Adherence  
Type:     Secondary  
Time Frame:    Intervention   
Brief Description:  Homework assignment adherence is a measure of treatment feasibility. D uring the 
intervention period, participants in the MBCT groups will be asked to record the 
amount of assigned home- based practice they completed each day.  
Name:     Su rvey Acceptability Questions   
Type:     Secondary  
Time Frame:    M0, M1, M2  
Study number:  s20-01911   Page 20 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Brief Description:   The Acceptability Questions are a measure of treatment acceptability and are to be 
administered at the end of each time point. 7 questions assess perceived 
acceptability of preceding surveys. Response options for questions 1- 6 range from 
Strongly Disagree to Strongly Agree on a 4- point Likert Scale. Question 7 is open -
ended to allow for free- form participant responses.  
Name:     Qualitative Questions  
Type:     Secondary  
Time Frame:    M2 
Brief Description:   Some participants (approximately 3- 4 from each cohort) will be invited to provide 
post-intervention qualitative feedback about the feasibility and acceptability of the 
study procedures and intervention. Questions are open- ended and cover topics 
related to the questionnaires, study procedures, and intervention.  
 
7.2.1.6  Details of Additional Data Collection by Study Personnel  
 
Name:    R ecruitment Rate  
Type :    Primary  
Time Frame :   Screening/M -1 
Brief Description :  Recruitment rate assesses study feasibility. Recruitment rate will describe the 
proportion of participants who screened positive on the electronic eligibility screener 
(denominator) and who enroll in the study at the end of the in- person intake visit at 
Month - 1 (numerator).   
Name:     MBC T-T Adherence and Competence Scale (MBCT -TACS)  
Type:     Primary  
Time Frame:   M2 
Brief Description:    The MBCT -TACS Adherence Scale assesses treatment fidelity. It is an adapted 
version of the MBCT -Adherence Scale, which has been widely used to evaluate 
fidelity to the 8- week in- person MBCT protocol. The MBCT -T Adherence and 
Competence scale was developed by Dr. Shallcross and is pending publication. 
Adherence (Primary Outcome) is rated separately for: a) inclusion of formal 
components (e.g., homework assigned, guided exercise, inquiry, etc.) and b) teaching goals (e.g., learning to place and hold attention, recognizing aversion, etc.) for each session on a 0- 3 scale. Competence (Secondary Outcome) is the ability to 
cultivat e a therapeutic group- based learning environment and capacity to embody 
mindfulness skills and is rated separately on a scale of 0- 3. Minimal expected fidelity 
in order to be considered “faithful” is an average score across sessions of ≥  2.5 for 
both adher ence and competence.   
Name:     Tr
 eatment Session Adherence 
Type:     Primary  
Time Frame:   Intervention   
Brief Description:   Treatment Session Adherence is a measure of treatment feasibility. The number of 
MBCT -T treatment sessions attended will be recorded and software will record the 
number of EUC education modules read by each participant. A treatment arm will be considered feasible if participants attended/read 75% of sessions on average. 
 
Name:     Fidelity Checklist  
Type:     Secondary  
Time Frame:    Intervention  
Brief Description:   The checklists cover the rundown and activities of each mindfulness session based 
on content within the treatments.  
Study number:  s20-01911   Page 21 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Name:     Survey Completeness  
Type:     Secondary  
Time Frame:    M0, M1,  M2, M3, M6, M9  
Brief Description:   Survey completeness assesses study feasibility. Survey completeness is a person-
level variable that will describe the proportion of surveys completed by each 
participant still enrolled in the trial at each survey administration.  
Name:     Ret ention Rate  
Type:     Primary  
Time Frame:    M2 
Brief Description:   Retention rate assesses study feasibility. Retention rate will describe the proportion 
of participants who were randomized to a treatment arm (denominator) who complete 
the primary clinical outcomes (Headache Disability Inventory and Quick Inventory of Depressive Symptomatology – Self-Report 16) at the primary clinical endpoint (Month 
2).  
Name:     Dai
 ly Diary Completeness  
Type:     Secondary  
Time Frame:    M0, M1, M2, M3  
Brief Description:   Daily diary completeness assesses study feasibility. Daily diary completeness is a 
person- level variable that will describe the number of days on which participants 
record headache activity during each month (28- day period).   
Name:    At trition  
Types:     Secondary  
Time Frame:    M1, M2, M3, M6, M9  
Brief Description :  Attrition assesses study feasibility. Attrition describes the proportion of individuals 
who have dropped out of the study at each time point.  
 
7.2.2  Concomitant Medications, Treatments, and Procedures 
 All standard of care (SOC) concomitant prescription medications  taken during study participation will be 
recorded on the case report forms (CRFs). For this study, a prescription medication is defined as a medication that can be prescribed only by a properly authorized/licensed clinician. Medications to be reported in the CRF are concomitant prescription medications, over -the-counter medications and non- prescription 
medications.  
 
7.2.3  Post -Intervention Materials 
After study participants have completed the Month 9 assessment, the unmasked research assistant at each site will unmask the participants to study interventions and will provide the patient manual for remote- delivered 
MBCT and the EUC modules to participants who did not receive these materials during the study.  
  
8 Assessment of Safety  
8.1 Specification of Safety Parameters  
This trial will be conducted in compliance with the current version of the protocol, current Good Clinical Practice, the principles of the Declaration of Helsinki, and all other applicable regulatory requirements. Annual progress reports and local Serious  Adverse Event (SAE) reports will be submitted to the IRB . 
Study number:  s20-01911   Page 22 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Monitoring will include regular monitoring for adverse events by the study team. In addition to reporting AEs 
and SAEs to the IRB according to standard guidelines, the investigators with appropriate expertise will regularly 
review SAEs and AEs at each weekly study meeting in order to rapidly address these events and to facilitate 
early recognition of any emerging patterns.  Specifically, the licensed neurologist Co- I will make determinations 
regarding psychiatric AEs and SAEs.  Additionally, the participants in this study will receive weekly depressive 
symptom monitoring during the intervention period. This close clinical monitoring should further facilitate early recognition of any concerning AE or SA E patterns.  
All efforts will be made to keep the identities of the participants private, and participants will be reminded of the 
potentially sensitive matters that may be discussed and to keep these discussions private. Confidentiality and 
privacy will b e discussed and mentioned specifically during the informed consent process. Each site’s research 
team will be responsible for direct communication with their site’s clinical patients.  
We will increase safety by excluding from enrollment patients at increased risk of adverse events from study treatments (e.g., those with active suicidal ideation, psychosis, and other criteria considered contraindicated in MBCT). Off -protocol care for mental health will not be restricted for any participants, regardless of group to 
which they are assigned during the trial.   
Dr. Shallcross  was trained in suicide assessment by faculty from Thomas Joiner's Laboratory for the Study and 
Prevention of Suicide- Related Conditions and Behaviors at Florida State University  and has ext ensive 
experience monitoring suicidal ideation and training research coordinators, assistants, and interventionists and implementing suicide safety plan  from her previous clinical trials with patients with a severe history of recurrent 
major depressive dis order and elevated depressive symptoms.  
All RAs  w
ill be required to complete a suicide assessment and prevention training sponsored by the Suicide Prevention Resource Center ( https://zerosuicidetraining.edc.org/ ). The licensed neurologist Co- I at each sit e 
will be available to oversee psychiatric SAEs.  
8.1.1  Definition of Adverse Events (AE)  
 An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity during 
the course of the study. Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests 
• is considered by the investigator to be of clinical significance  
8.1.2  Definition of Serious Adverse Events (SAE)  
 Serious Adverse Event  
Adverse events are classified as serious or non- serious.  A serious adverse event  is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospital stay  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significance. They may  jeopardize the subject, and may require intervention to prevent one of the other serious 
outcomes noted above.  For example, drug overdose or abuse, a seizure that did not result in in- patient 
Study number:  s20-01911   Page 23 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  hospitalization, or intensive treatment of bronchospasm in an emergency department would typically be 
considered serious.  
 All adverse events that do not meet any of the criteria for serious should be regarded as non -serious 
adverse events.  
 
8.1.3  Definition of Unanticipated Problems (UP)  
 
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all  of  the following criteria:  
• Unexpected in nature, severity, or frequency  (i.e. not described in study -related documents such as 
the IRB -approved protocol or consent form, the investigators brochure, etc .) 
• Related or possibly related to participation in the research ( i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by the 
procedures involved in the resear ch) 
• Suggests that the research places subjects or others at greater risk of harm  ( including physical, 
psychological, economic, or social harm).  
 
8.2 Classification of an Adverse Event  
8.2.1  Severity of Event  
 For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic measures. 
Moderate events may cause some interference with functioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug therapy or  
other treatment. Severe events are usually potentially life- threatening or incapacitating.  
8.2.2  Relationship to Study Intervention  
 The clinician’s assessment of an AE's relationship to study intervention  is part of the documentation process, 
but it is not a f actor in determining what is or is not reported in the study. If there is any doubt as to whether a 
clinical observation is an AE, the event should be reported. All AEs must have their relationship to study 
intervention assessed. In a clinical trial, the s tudy intervention must always be suspect. To help assess, the 
following guidelines are used.  
 
• Related – The AE is known to occur with the study intervention, there is a reasonable possibility that 
the study intervention caused the AE, or there is a temporal relationship between the study 
intervention and event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study intervention  and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study intervention 
caused the event, there is no temporal relationship between the study intervention and event onset, or 
an alternate etiology has been established.  
8.2.3  Expectedness 
 
Study number:  s20-01911   Page 24 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  PIs and Co- Is at each site will be responsible for determining whether an AE is expected or unexpected. An 
AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the 
risk information previously described for the study intervention.  
8.3 Time Period and Frequency for Event  Assessment and Follow -Up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate RF. Information to be collected includes event description, time of onset, clinician’s assessment of severity, relationship to study intervention (assessed only by those with the training and authority to make a diagnosis), 
and time of resolution/stabilization of the event. All AEs occurring while on study must be documented 
appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
 Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout 
the study.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each episode.  
 The PI will record all reportable events with start dates occurring any time after informed consent is obtained. SAEs will be followed until resolutions are reached as stated below. AEs will be followed for the duration of an individual’s participation in the study. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.   
 
All unresolved adverse events should be followed by the investigator until the events are resolved, the subject 
is lost to follow -up, or the adverse event is otherwise explained.  At the last scheduled visit, the investigator 
should instruct each subject  to report any subsequent event(s) that the subject, or the subject’s personal 
physician, believes might reasonably be related to participation in this study.  The investigator should notify the study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participation that may reasonably be related to this study.  
 
8.4 Reporting Procedures – Notifying the IRB  
It is the investigator’s responsibility at each site to report UPs to their IRB  in accordance with each site ’s 
reporting policies. All UPs at sites other than NYU also need to be reported to the sIRB at NYU Grossman SOM/ NYULH.   
8.5 Reporting Procedures – Notifying the Study Sponsor  
The study clinician will complete a SAE Form within th e following timelines:  
 
• All deaths and immediately life- threatening events, whether related or unrelated, will be recorded on 
the SAE Form and submitted to the DCC/study sponsor within 24 hours of site awareness. See Section 1, Key Roles for contact inform ation.  
• Other SAEs regardless of relationship will be submitted to the DCC/study sponsor within 72 hours of site awareness.  
 All SAEs will be followed until satisfactory resolution or until the site investigator deems the event to be 
chronic or the adherence to be stable. Other supporting documentation of the event may be requested by the 
DCC/study sponsor and should be provided as soon as possible.  
 
Study number:  s20-01911   Page 25 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  As a follow -up to the initial report, within the following 48 hours  of awareness of the event , the investigator 
shall provide further information, as applicable, on the unanticipated event or the unanticipated problem in the 
form of a written narrative.  This should include a copy of the completed Unanticipated Problem form, and any 
other diagnostic information that will assist the understanding of the event.  Significant new information on ongo ing unanticipated adverse effects shall be provided promptly to the study sponsor.  
8.6 Safety Oversight  
It is the responsibility of the Principal Investigator an d clinician on the study to oversee the safety of the study.  
Each site’s PI and clinician will also provide safety monitoring at their location.  This safety monitoring will 
include careful assessment and appropriate reporting of adverse events as noted above, as well as the 
construction and implementation of a site data and safety -monitoring plan. Medical monitoring will include a 
regular assessment of the number and type of serious adverse events.  
 
9 Statistical Considerations  
9.1 Description of Statistical Meth ods 
Basic descriptive statistics (e.g., means and standard deviations, frequencies and percentages, or medians and 
interquartile ranges) for variables of interest will be computed. Distributions of each variable will be examined. Graphical approaches will be used to further explore the data where appropriate. Differences in demographics and clinical characteristics at baseline will be evaluated across the three treatment arms. No missing data is 
anticipated for treatment fidelity or treatment feasibility primary outcomes. For the CSQ -8, missing data will be 
singly -imputed as the lowest possible score on the CSQ -8, indicating dissatisfaction with the treatment. For 
clinical utility responder rates, missing data will be singly -imputed as non- response to treatment. For secondary 
outcome analysis, missing data will be estimated as part of the mixed models procedures. Primary analyses 
will not be adjusted. Any significant differences on demographic variables between treatment groups will be 
included as covariates in secondary adjusted models of the secondary analyses described below. SPSS, SAS 
and R will be used to conduct the analyses. All tests will be two- tailed with alpha set at 0.05.  
Aim 1A. Demonstrate fidelity to MBCT -T and MBCT -V protocols across sites.   
Hypothesis (H)1 : MBCT -T and MBCT -V sessions (n = 96 sessions) will be administered faithfully 
[MBCT -TACS scores ≥ 2.5] across treatment arm (MBCT -T vs. MBCT -V) and site (n = 3).  
Descriptive statistics (mean and standard deviation) will be calculated for the MBCT -TACS in total (n = 96) and 
across each treatment arm (MBCT -T, session n = 48 vs. MBCT -V, session n = 48); both treatment arms will be 
considered administered faithfully if  mean MBCT -TACS scores are ≥ 2.5. Descriptive statistics (mean and 
standard deviation) will be calculated for the MBCT -TACS across  each treatment site (NYULH, Einstein, and 
WFBH n = 32); a site will be considered to have administered the interventions faithfully if mean MBCT -TACS 
scores are ≥ 2.5.  
Aim 1B. Demonstrate feasibility and acceptability of MBCT -T, MBCT -V, and EUC.  
H1:  MBCT -T, MBCT -V, and EUC will be feasible [Primary Outcome: 75% Session Attendance] and 
acceptable [Primary Outcome: Client Satisfaction Questionnaire- 8 (CSQ -8) score > 24] at each site.  
Feasibility is assessed using Treatment Session Adherence (n = 144), which will be summed to indicate the number of treatment sessions attended. Descriptive statistics (mean and standard deviation) will be calculated 
for Treatment Session Adherence across each treatment arm (MBCT -T, MBCT -V, EUC) and each site (NYULH, 
Montefiore, WFBH ). A treatment arm will be considered feasible if on average participants attended 75% of 
sessions, across all sites. A site will be considered to demonstrate adequate feasibility if on average participants 
attended 75% of sessions across treatment arms at the site.  
Study number:  s20-01911   Page 26 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Acceptability is assessed using the CSQ -8 at a single time -point. Descriptive statistics (mean and standard 
deviation) will be calculated for the CSQ -8 across each treatment arm (MBCT -T, MBCT -V, EUC) and each site 
(NYULH, Montefiore, WFBH ). Investigators will endeavor to obtain CSQ -8 scores from all participants; if 
participants drop out of the study prior to Month 2 and cannot be reached to complete this measure, a t otal 
score of 8 will be imputed for these missing data, indicating dissatisfaction with the treatment across all domains. 
A treatment arm will be considered acceptable if CSQ -8 scores are >  24, across all sites. A site will be 
considered to demonstrate adequate acceptability if on average participants report CSQ -8 scores > 24 across 
treatment arms at the site.  
Aim 1C. Demonstrate feasibility of study procedures (primary outcomes: recruitment and retention).  
H1: Recruitment rate will be ≥ 40% at each site.  
H2: Retention rate will be ≥ 75 % at each site and in each arm.   
Feasibility will be assessed using both recruitment and retention rate. Recruitment rate is the proportion of 
individuals who passed the online eligibility screen (denominator) who enroll in the study at the Month -1 in-
person intake session (numerator). Retention rate is the proportion of participants who were randomized to 
treatment arm (denominator) who complete the primary clinical outcomes at Month 3 (numerator). Both 
recruitment and retention rates will be calculated for each site. A site will be considered to demonstrate 
adequate feasibility of study procedures if the recruitment rate is ≥ 40% and the retention rate is ≥ 75%. An arm 
will be considered to demonstrate adequate study feasibility if the retention rate is ≥ 75 %. 
Sample Size Justification and Power for Aim 1 
The n = 144 will allow each site to have 2 treatment groups within each MBCT treatment arm and maintain 
1:1:1 treatment arm assignment; for example, at the NYULH site, the total n = 48: MBCT -T (2 treatment groups, 
n = 16 per site), MBCT -V (2 treatment groups, n = 16 per site) and EUC (n = 16 per site).   
Power calculations were informed by preliminary data (Ms, SDs). For Aim 1A, 100% of sessions met the benc
hmark in preliminary testing; within a 95% CI, we will have power above .99 to detect a mean fidelity score 
at or above the benchmark. For Aim 1 B, 87% of participants met benchmarks for both feasibility and 
acceptability in preliminary testing; within a 95% CI we will have power above .89 to detect mean feasibility and acceptability  score at or above the benchmarks. For Aim 1C hypothesis 1, we will be able to estimate a 
recruitment rate of 40% to within a 95% confidence interval of +/ - 5% for the study overall (enrolled n = 144) 
and +/ - 9% for each site (enrolled n = 48). For Aim 1 C hypothesis 2, we will be able to estimate a retention rate 
of 70% to within a 95% confidence interval of +/ - 7% for the study overall and (n = 144) +/ - 13% for each site (n 
= 48).  
Aim 2. Use decision rules to determine design for future fully -powered Phas e III trial.  
Decision Rules  
Decision rules will be assessed using data pooled across sites to reduce multiple comparisons and discrepant 
findings across sites. However, we anticipate that certain sites will have strengths and weaknesses related to 
feasibility and acceptability outcomes. We hope to use ongoing monitoring to identify weaknesses during the 
study and implement procedures to improve sites falling behind on outcome parameters. We also will evaluate 
feasibility information at each site to determine whether to keep/remove the site for a future trial, or whether the 
site (and other potential sites with similar characteristics) requires different resources to be successful.  
Decisions rules are based on three levels where we will consider benchmarks, clinically important differences 
(CIDs) between groups, and statistical significance.  
Benchmarks (MBCT -T and MBCT -V): MBCT -T and MBCT -V will need to meet minimum benchmarks for 
primary outcomes (fidelity, feasibility, and acceptability) across treatment arm and site. Primary outcomes: 
Study number:  s20-01911   Page 27 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Fidelity  (MBCT -TACS scores ≥ 2.5) , Feasibility of treatment (75% Session Attendance) , Acceptability of 
treatment  (Client Satisfaction Questionnaire- 8 (CSQ -8) score > 24) , Feasibility of study procedures  
(recruitment rate will be ≥ 40%; retention rate will be ≥ 75 %). 
If one or more of these thresholds is not met for MBCT -T or MBCT -V for all sites, we will examine secondary 
outcomes to help determine the cause of suboptimal performance, make changes to the treatment arm and/or 
site, and/or conduct an additional pilot to rectify performance. If thresholds are not met for treatment arm, we 
will no t move forward with a future trial with either MBCT -T or MBCT -V. If thresholds are not met for site, we 
will ascertain whether the identified barrier to fidelity, feasibility, and/or acceptability is modifiable. If barrier is 
deemed to be unchangeable, we will consider dropping the site in fully -powered trial.  
Benchmarks (EUC):  EUC will need to meet minimum thresholds for feasibility and acceptability indicated 
above. If either or both of these domains are not met, we will use secondary outcomes to improve feasibility 
and/or acceptability in future pilot testing prior to moving forward with the fully -powered Phase III clinical trial. If 
both acceptability and feasibility benchmarks are met for EUC, we will move forward with EUC in a future Phase 
III trial.  
Clinically Important Differences (CIDs) and statistical significance  
If minimum benchmarks (see above) for all arms are met, we will move forward with both MBCT -T and MBCT -
V vs. EUC in a fully-powered Phase III clinical trial so long as neither version of MBCT is superior to the 
other based on the following analyses : 
1) MBCT -T/V Treatment  fidelity : MBCT -TACS is at least ≥0.2 points higher in the superior compared to 
the inferior arm, and this difference is statistically significant.  
2) MBCT -T/V Treatment  feasibility  is at least 15% higher in the superior arm compared to the inferior 
arm, and this difference is statistically significant.  
3) MBCT -T/V Treatment  acceptability is at least 5 points higher in the superior arm compared to the 
inferior arm, and this difference is statistically significant.  
4) MBCT -T/V Clinical utility : 50% responder rate for the HDI (10- point change from M0- M3) and the 
QIDS -SR (5 -point change from M0- M3). No significance testing between MBCT -T and MBCT -V will be 
conducted for this outcome.  
If one of the above criteria is met (i.e., one treatment meets threshold for being superior to the other), we will 
select this treatment to move forward with further testing in a fully -powered Phase III trial.  
If we observe mixed results (e.g., MBCT -T is superior on feasibility but MBCT -V is superior on clinical utility) 
we will utilize results from secondary outcomes to further explore differences between the MBCT -T and MBCT -
V treatment arms to inform the selection of treatment arms for the Phase III trial.  
Analyses 
Mixed effects models will evaluate whether treatment fidelity, treatment feasibility, or treatment acceptability 
differ significantly between MBCT -T and MBCT -V. Alpha will be set at 0.05 for all ana lyses.  
To evaluate differences in fidelity, a multi- level linear mixed effects model will evaluate differences between 
MBCT -T and MBCT -V on the MBCT -TACS (72 sessions nested in 6 treatment groups). Treatment site will be 
included as a covariate. Repeated measures will be taken into account using session- level random effects.  
To evaluate differences in feasibility and acceptability, two separate multi -level linear mixed effects model will 
be used to evaluate differences between MBCT -T and MBCT -V on Treatment Session Adherence and the 
CSQ -8 (96 participants nested in 6 treatment groups). Treatment site will be included as a covariate. C lusters 
Study number:  s20-01911   Page 28 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  by group membership will be taken into account using random effects . Power for Aim 2 . Using SDs and ICCs 
derived from preliminary data, with an n = 96 sessions and n = 96 participants, we have at least a power of .90 
to detect the clinically important differences (CIDs) pre- specified in the decision rules for treatment fidelity 
(MBCT -TACS CID = 0.2 points; power > .99), treatment feasibility (Treatment Session Adherence CID = 15%; 
power > .99) and treatment acceptability (CSQ -8 CID = 5 points; power = .91).  
Planned Secondary Analyses  
Descriptive statistics (means and standard deviations or ns and %s) will be calculated for all secondary 
out
comes. Secondary outcomes for Aim 1 will be assessed via: 1) daily diary (Homework Adherence during 
intervention, Headache Frequency, Pain Intensity); 2) monthly survey (Headache Disability Inventory, QIDS -
SR (depressive symptoms), MBCT Home Practice inventory, Migraine- Specific Quality of Life, Co- occurring 
Treatment Tracking, Adverse Events); or administrative data (Survey Completeness, Diary Completeness and Attrition). For secondary outcomes evaluated w ith daily diary, multi- level mixed effects models will evaluate 
changes in the outcomes at the day -level across treatment arm (MBCT -T vs. MBCT -V vs. EUC). Repeated 
measures (day) within person will be taken into account by using person- level random effects . Clusters by group 
membership will be taken into account using a random effect. Treatment site will be included as a covariate. For secondary outcomes evaluated with monthly surveys, multi -level mixed effects models will evaluate 
changes in the outcomes at the month- level across treatment arm (MBCT -T vs. MBCT -V vs. EUC). Repeated 
measures (month) within person will be taken into account by using person- level random effects. Treatment 
site will be included as a covariate.  
 
9.2 Measures to Minimize Bias  
9.2.1  Enrollm ent /Masking Procedures 
Subjects will be masked to study hypotheses. They will be informed that they will be assigned to one of three 
interventions that will last a maximum of 8 weeks and that will provide knowledge to help migraine and depressive symptoms. The facilitators will be unmasked. Data will be entered and coded so that group membership is known only to the project coordinator at NYULH and to research assistants who are coordinating study visits. The investigators  will be masked to treatment condition. After study subjects  have 
completed the post -intervention/M2 assessment, the unmasked research assistant will unmask the subject s 
to study interventions . 
Blinded Personnel: 
Amanda Shallcross (mPI)  
Elizabeth Seng (mPI)  
Cuiling Wang (statistician)  
YU Research Assistant (data management)  
Richard Lipton (Co- I) 
Mia Minen (Co- I) 
Rebecca Wells (Co- I) 
 
Unblinded Personnel:  
NYU Program Coordinator (randomization scheme)  
Einstein Psychology Assistant (randomization scheme)  
Wake Forest Research Assistant (randomization scheme)  
Interventionists  at each site  
YU Research Assistant - Facilitator (Einstein intervention delivery)  
Source Documents and Access to Source Data/Documents 
Study number:  s20-01911   Page 29 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Source data is all information, original records of clinical findings, observations, or other activities in a clinical 
trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source 
documents.  Examples of these original documents, and data records include: hospital records, clinical and 
office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from  automated instruments, copies or transcriptions certified after verification as 
being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, 
subject files, and records kept at the pharmacy, at the laboratories, and at medico- technical departments 
involved in the clinical trial.   
 The study case report form (CRF) is the primary data collection instrument for the study.  All data requested on the CRF must be recorded.  All missing data must be explained.  If a space on the CRF is left blank because the procedure was not done or the question was not asked, write “N/D”.  If the item is not applicable to the individual case, write “N/A”.  All entries should be printed legibly in black ink.  If any entry error has been made, to correct such an error, draw a single straight line through the incorrect entry and enter the 
correct data above it.  All such changes must be initialed and dated.  DO NOT ERASE OR WHITE OUT 
ERRORS.  For clarification of illegible or uncertain entries, print the clarification above the item, then initial and date it.  
 Access to study records will be limited to IRB -approved members of the study team. The investigator will 
permit study -related monitoring, audits, and inspections by the IRB/EC , the sponsor, government regulatory 
bodies, and University compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.).  The investigator will ensure the capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.).  
 Participation as an investigator in this study implies acceptance of potential inspection by government 
regulatory authorities and applicable University  compliance and quality assurance offices.  
 
10 Quality Assurance and Quality Control  
 
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
 
Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, 
documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities.  
 
11 Ethics/Protection of Human Subjects  
11.1 Ethical Standard  
 The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46.  
 
11.2 Institutional Review Board  
 
The protocol, key information form, consent forms, recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and consent materials must be 
Study number:  s20-01911   Page 30 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  obtained before any participant is enrolled. Any amendment to the protocol will require review and approval 
by the IRB before the changes are implemented to the study. All changes to the consent form  will be IRB 
approved; a determination will be made regarding whether previously consented participants need to be re-consented.  
11.2.1  Independent (non -NYULH, third party) certified MBCT instructors  
 
If individuals  are engaged in human subjects research based on OHRP definition , they are required to obtain 
their own IRB approval before human subjects research activities are performed.  
 
I
f individuals are not engaged in human subjects research, PI will ensure there is an executed Business 
Associate Agreement (BAA) in place before any proposed work is performed by those individuals as 
contractors. Individuals are considered not engaged in human subjects research if they perform commercial 
or other services for investigators provided that  all of the following conditions also are met:  
 
• the services performed do not merit professional recognition or publication privileges  
• the services performed are typically performed by those individuals for non- research purposes  
• those individuals do not administer any study intervention being tested or evaluated under the protocol  
 
11.3 Informed Consent Process  
11.3.1  Consent and Other Informational Documents Provided to Participants 
 The following consent materials are submitted with this protocol:  
 
• Study 2  Key Information Sheet  
• Study 2  Consent Form  
• Study 2  Audio Consent  
11.3.2  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and 
continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of 
participation will be provided to the subjects and their families  via telephone or WebEx video- conferencing. 
Consent forms will be IRB -approved and individuals will be asked to read and review the document. 
Individuals will have the opportunity to carefully review the e-Consent  materials  and ask questions prior to 
signing in REDCap. Individuals should have the opportunity to discuss the study or think about it prior to 
agreeing to participate. Subjects  will sign the e-Consent in REDCap prior to any procedures being done 
specifically for the study.  Subjects may withdraw consent at any time throughout the course of the trial. A 
copy of the signed  informed consent document will be provi ded via REDCap to the participants for their 
records. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.  
 
A copy of the signed informed consent document will be stored in the subject’s research record. The consent 
process, including the name of the individual obtaining consent, will be thoroughly documented in the 
subject’s research record. Any alteration to the standard consent process (e.g. use of a translator, consent from a legally authorized representative, consent document presented orally, etc.) and the justification for such alteration will likewise be documented.  
The R EDCap e- Consent link will be submi tted to the IRB for review in Research Navigator via Modification.  
Study number:  s20-01911   Page 31 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  11.4 Subject and Data Confidentiality  
Information about study subjects will be kept confidential and managed according to the requirements of the 
Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a signed 
subject authorization informing the subject of the following:  
 
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains the ability to use all information collected prior to the revocation of subject authorization.  For subjects that 
have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at 
least vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
 
Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and genetic 
tests in addition to the clinical information relating to participants. Therefore, the study protocol, 
documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.  
 The study monitor, other authorized representatives of the sponsor, or representatives of the IRB may inspect 
all documents and records required to be m aintained by the investigator, including but not limited to, medical 
records (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study 
site will permit access to such records.  
 The study participant’s contact  information will be securely stored at for internal use during the study. At the 
end of the study, all records will continue to be kept in a secure location for as long a period as dictated by 
IRB and Institutional regulations.  
 
To further protect the privacy of study participants, a Certificate of Confidentiality will be obtained from the NIH. This certificate protects identifiable research information from forced disclosure. It allows the investigator and others who have access to research records to refuse to disclose identifying information on research participation in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, 
or local level. By protecting researchers and institutions from being compelled to disclose information that 
would identify research participants, Certificates of Confidentiality help achieve the research objectives and promote participation in studies by helping assure confidentiality and privacy to participants.  
 
11.4.1  Research Use of Stored D ata 
• Intended Use: Data collected under this protocol may be used to study migraine and depression. No genetic testing will be performed.  
• Storage: Data will be stored using codes assigned by the investigators. Data will be kept in  NYU’s  
REDCap  system . All three research sites included in this protocol will use NYU’s REDCap for data 
storage and management.  Only investigators will have access to the data.  
• Tracking: Data will be tracked using NYU’s  REDCap.  
 
12 Data Handling and Record Keeping  
12.1 Data Collection and M anagement Responsibilities  
 
Study number:  s20-01911   Page 32 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  Data collection is the responsibility of the clinical trial staff at the site under the supervision of the PI. The 
investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data 
reported.  
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink is required to ensure clarity of reproduced copies. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE 
CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 Copies of the electronic CRF (eCRF) will be provided for use as source documents and maintained for recording data for each participant enrolled in the study. Data reported in the eCRF derived from source documents should be consistent with the source documents or the discrepancies should be explained and captured in a progress note and maintained in the participant’s official electronic study record.  
 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data will be entered into RED Cap. The data system includes password protection and internal 
quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or 
inaccurate. Clinical data will be entered directly from the source documents.  
 
12.2 Study Records Retention  
Study documents will be retained for the longer of 3 years after close out or 5 years after final reporting/publication. These documents should be retained for a longer period, however, if required by local regulations. No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained.  
 
12.3 Protocol Deviations  
 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or MOP requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by the site and implemented promptly.  
 These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 Protocol deviations must be reported to the local IRB per their guidelines. The PI/study staff is responsible for knowing and adhering to their IRB requirements. Further details about the handling of protocol deviations will 
be included in the MOP.  
 
12.4 Publication and Data Sharing Policy  
This study will comply with the NIH Public Access Policy, which ensures that the public has access to t he 
published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication.  
 
13 Study Finances  
13.1 Funding Source  
This study is financed through a grant from NIH -NCCIH. 
Study number:  s20-01911   Page 33 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019   
13.2 Costs to the Subject  
Subjects  will incur no cost as a result of participating in the study.  
 
13.3 Subject Reimbursements or Payments  
 
Participants will each be compensated $15 for 7 assessment points (Intake & Months 0, 1, 2, 3, 6 , and 9)  ($105 
total for assessments). Participants will be compensated $30 for each diary (30 days, $1/day) completed during 
the month- long run- in period and over the course of three months (M0- M3) ($120 total for diaries). In total, each 
participant will have an opportunity to be compensated up to $2 25 over the course of the study.  Participants 
will be compensat ed with a single payment at the end of their participation in the study. If a participant withdraw s 
from the study for any reason, they will be compensated for all completed assessment points up to the time of withdrawal. Participant compensation accrued during the study will be tracked by the study data manager and 
reported back to the participants throughout their participation in the study to keep them informed of the compensation accrual amount.  Payments will be provided via check through the NYU PeopleSoft financials 
application . 
 
14 Study Administration 
14.1 Sites  
 Involved in Human Subjects Research:  
• N
YU Langone: Will oversee study administration, recruitment, data collection, and data monitoring.  
• Yeshiva University : Will assist with recruitment  at Montefiore Health System, data collection, and data 
monitoring.  
• Albert Einstein College of Medicine: Will conduct recruitment at Montefiore Health System  
• Atrium Health Wake Forest Baptist : Will conduct recruitment, data collection, and data monitoring.  
 
15 Conflict of Interest  Policy  
The independence of this study from any actual or perceived influence, such as by the pharmaceutical 
industry, is critical. Therefore, any actual conflict of interest of persons who have a role in the design,  conduct, 
analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, persons who 
have a perceived conflict of interest will be required to have such conflicts managed in a way that is appropriate to their participation in the trial. The study leadership in conjunction with the NCCIH has 
established policies and procedures for all study group members to disclose all conflicts of interest and will 
establish a mechanism for the management of all reported dualities of interest.   
 
Any investigator who has a conflict of interest with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by the NYU Langone Conflict of Interest Committee with a Committee- sanctioned conflict management plan that has been 
reviewed and approved by the study sponsor prior to participation in this st udy.  All NYULH  investigators will 
follow the  applicable conflict of interest policies .
 
16 References  
 
1. Classification Committee of the International Headache Society. The International Classification of 
Headache Disorders, 3rd edition. Cephalalgia 38, (2018).  
2. Institute for Health Metrics and Evaluation. Global Burden of Disease Study Data Resources . 
Study number:  s20-01911   Page 34 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  http://ghdx.healthdata.org/gbd- 2017 (2017).  
3. Lipton, R. B. et al.  Migraine prevalence, disease burden, and the need for preventive therapy. Neurology  
(2007) doi:10.1212/01.wnl.0000252808.97649.21.  
4. Burch, R. C., Loder, S., Loder, E. & Smitherman, T. A. The prevalence and burden of migraine and 
severe headache in the United States: Updated statistics from government health surveillance studies. 
Headache (2015) doi:10.1111/head.12482.  
5. Buse, D. et al.  Headache impact of chronic and episodic migraine: Results from the American Migraine 
Prevalence and Prevention Study. Headache (2012) doi:10.1111/j.1526- 4610.2011.02046.x.  
6. Silberstein, S. D. et al.  Evidence- based guideline update: Pharmacologic treatment for episodic migraine 
prevention in adults report of the quality standards subcommittee of the American academy of neurology and the american headache society. Neurology  (2012) doi:10.1212/WNL.0b013e3182535d20.  
7. Holland, S. et al.  Evidence -based guideline update: NSAIDs and other complementary treatments for 
episodic migraine prevention in adults Report of the quality standards subcommittee of the american academy of neurology and the American headache society. Neurology  (2012) 
doi:10.1212/WNL.0b013e3182535d0c.  
8. Penzien, D. B., Irby, M. B., Smitherman, T. A., Rains, J. C. & Houle, T. T. Well -Established and 
Empirically Supported Behavioral Treatments for Migraine. Current Pain and Headache Reports  (2015) 
doi:10.1007/s11916- 015-0500- 5. 
9. Halker Singh, R. B., Ailani, J. & Robbins, M. S. Neuromodulation for the Acute and Preventive Therapy of Migraine and Cluster Headache. Headache (2019) doi:10.1111/head.13586.  
10. Blumenfeld, A. M. et al.  Disability, HR QoL and resource use among chronic and episodic migraineurs: 
Results from the International Burden of Migraine Study (IBMS). Cephalalgia  (2011) 
doi:10.1177/0333102410381145.  
11. Buse, D. C., Silberstein, S. D., Manack, A. N., Papapetropoulos, S. & Lipton, R. B. Psychiatric comorbidities of episodic and chronic migraine. Journal of Neurology  (2013) doi:10.1007/s00415- 012-
6725- x. 
12. Vetvik, K. G. & MacGregor, E. A. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. The Lancet Neurology  (2017) doi:10.1016/S1474- 4422(16)30293- 9. 
13. Yang, Y. et al.  Shared Genetic Factors Underlie Migraine and Depression. Twin Res. Hum. Genet.  
(2016) doi:10.1017/thg.2016.46.  
14. Ma, M. et al.  Exploration of intrinsic brain activity in migraine with and without comorbid depression. J. 
Headache Pain (2018) doi:10.1186/s10194- 018-0876- 9. 
15. Seng, E. K. et al.  Psychological Factors Associated With Chronic Migraine and Severe Migraine- Related 
Disability: An Observational Study in a Tertiary Headache Center. Headache (2017) 
doi:10.1111/head.13021.  
16. Ashina, S. et al.  Depression and risk of transformation of episodic to chronic migraine. J. Headache Pain 
(2012) doi:10.1007/s10194 -012-0479- 9. 
17. Rothrock, J. F. Opiate and opioid (‘Narcotic’) therapy for acute migraine headache. Headache (2010) 
doi:10.1111/j.1526- 4610.2010.01728.x.  
18. Buse, D. C. et al.  Opioid use and dependence among persons with migraine: Results of the ampp study. 
Headache (2012) doi:10.1111/j.1526- 4610.2011.02050.x.  
19. Pesa, J. & Lage, M. J. The medical costs of migraine and comorbid anxiety and depression. Headache 
(2004) doi:10.1111/j.1526- 4610.2004.446004.x.  
20. Kabat -Zinn, J. Full catastrophe living : Using the wisdom of y our body and mind to face stress, pain, and 
illness . (Delacorte Press, 1990).  
21. Li, S. Y. H. & Bressington, D. The effects of mindfulness -based stress reduction on depression, anxiety, 
and stress in older adults: A systematic review and meta- analysis. International Journal of Mental Health 
Nursing (2019) doi:10.1111/inm.12568.  
22. Ghawadra, S. F., Abdullah, K. L., Choo, W. Y. & Phang, C. K. Mindfulness -based stress reduction for 
psychological distress among nurses: A systematic review. Journal of Clinical  Nursing (2019) 
doi:10.1111/jocn.14987.  
23. Veehof, M. M., Trompetter, H. R., Bohlmeijer, E. T. & Schreurs, K. M. G. Acceptance- and mindfulness -
based interventions for the treatment of chronic pain: a meta- analytic review. Cognitive Behaviour 
Therapy  (2016) doi:10.1080/16506073.2015.1098724.  
24. Wells, R. E. et al.  Meditation for migraines: A pilot randomized controlled trial. Headache (2014) 
doi:10.1111/head.12420.  
Study number:  s20-01911   Page 35 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  25. Shapiro, S. L., Carlson, L. E., Astin, J. A. & Freedman, B. Mechanisms of mindfulness. Journal of Clinical 
Psychology  (2006) doi:10.1002/jclp.20237.  
26. Segal, Z. V. & Walsh, K. M. Mindfulness -based cognitive therapy for residual depressive symptoms and 
relapse prophylaxis. Current Opinion in Psychiatry  (2016) doi:10.1097/YCO.000000000000021 6. 
27. Segal ZV, Williams JMG, T. J. Mindfulness -Based Cognitive Therapy for Depression, 2nd edition. 
(Guilford Press, 2013).  
28. Strauss, C., Cavanagh, K., Oliver, A. & Pettman, D. Mindfulness -based interventions for people 
diagnosed with a current episode of an anxiety or depressive disorder: A meta- analysis of randomised 
controlled trials. PLoS One 9, e96110 (2014).  
29. Day, M. A. et al.  Mindfulness -based cognitive therapy for the treatment of headache pain: A pilot study. 
Clin. J. Pain (2014) doi:10.1097/AJP.0b013e318287a1dc.  
30. Parra -Delgado, M. & Latorre- Postigo, J. M. Effectiveness of mindfulness -based cognitive therapy in the 
treatment of fibromyalgia: A randomised trial. Cognit. Ther. Res.  (2013) doi:10.1007/s10608- 013-9538-
z. 
31. Dowd, H. et al.  Comparison of an online mindfulness -based cognitive therapy intervention with online 
pain management psychoeducation: A randomized controlled study. Clin. J. Pain  (2015) 
doi:10.1097/AJP.0000000000000201.  
32. Seng E, Singer A, Metts C,  et al. Does mindfulne ss-based cognitive therapy for migraine reduce 
migraine- related disability? Results from a Phase 2b Pilot Randomized Clinical Trial. Headache 59, 1–
2 (2019).  
33. Minen, M. T. et al.  Factors related to migraine patients’ decisions to initiate behavioral migraine treatment 
following a headache specialist’s recommendation: A prospective observational study. Pain Med. (United States)  (2018) doi:10.1093/pm/pny028.  
34. Segal, Z. V. et al.  Outcomes of Online Mindfulness -Based Cognitive Therapy for Patients with Residual 
Depressive Symptoms: A Randomized Clinical Trial. JAMA Psychiatry (2020) 
doi:10.1001/jamapsychiatry.2019.4693.  
35. Connolly, K. S. et al.  Nationwide Implementation and Outcomes of Cognitive Behavioral Therapy for 
Chronic Pain Over Clinical Video Teleconferencing. J. Technol. Behav. Sci.  (2018) doi:10.1007/s41347-
017-0024- 4. 
36. Egede, L. E. et al.  Psychotherapy for depression in older veterans via telemedicine: A randomised, 
open- label, non- inferiority trial. The Lancet Psychiatry  (2015) doi:10.1016/S2215- 0366(15)00122- 4. 
37. Krägeloh, C. U. et al.  A Pilot Randomized Controlled Trial for a Videoconference- Delivered Mindfulness -
Based Group Intervention in a Nonclinical Setting. Mindfulness (N. Y).  (2019) doi:10.1007/s12671- 018-
1024- y. 
38. Anderson, Monica; Kumar, M. Digital Divide Persists Even As Lower -Income Americans Still Lag in Tech 
Adoption. Pew Research Center  (2019).  
39. Federal Communications Commission. 2016 Broadband Progress Report . https://www.fcc.gov/reports -
research/reports/broadband- progress -reports/2016- broadband- progress -report (2016).  
40. Walker, D. M., Hefner, J. L., Fareed, N., Huerta, T. R. & McAlearney, A. S. Exploring the digital divide: 
Age and race disparities in use of an inpatient portal. Telemed. e -Health  (2020) 
doi:10.1089/tmj.2019.0065.  
41. Salmoirago- Blotcher, E. et al.  Phone- delivered mindfulness training for patients with implantable 
cardioverter defibrillators: Results of a pilot randomized control led trial. Ann. Behav. Med.  (2013) 
doi:10.1007/s12160- 013-9505- 7. 
42. Thompson, N. J. et al.  Distance delivery of mindfulness -based cognitive therapy for depression: project 
UPLIFT. Epilepsy Behav  19, 247– 254 (2010).  
43. Churchill, R. et al.  A systematic review of controlled trials of the effectiveness and cost -effectiveness of 
brief psychological treatments for depression. Health Technology Assessment  (2001) 
doi:10.3310/hta5350.  
44. Day, M. A. et al.  A Pilot Randomized Controlled Trial Comparing Mindfulness Meditation, Cognitive 
Therapy, and Mindfulness -Based Cognitive Therapy for Chronic Low Back Pain. Pain Med. (United 
States)  (2019) doi:10.1093/pm/pny273.  
45. Shallcross, Duberstein, Sperber, Visvanathan, Carmody, S. An Open Trial of Telephone- Delivered 
Mindfulness -Based Cognitive Therapy: Feasibility, Acceptability, and Preliminary Efficacy for Reducing 
Depressive Symptoms. Under Review.  
46. Martin, P. R. et al.  Cognitive behavior therapy for comorbid migraine and/or tension- type headache and 
Study number:  s20-01911   Page 36 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  major depressive disorder: An exploratory randomized controlled trial. Behav. Res. Ther.  (2015) 
doi:10.1016/j.brat.2015.07.005.  
47. Borrelli, B. The assessment, monitoring, and enhancement of treatment fidelity in public health clinical 
trials. J. Public Health Dent.  (2011) doi:10.1111/j.1752 -7325.2011.00233.x.  
48. Stubberud, A. & Linde, M. Digital Technology and Mobile Health in Behavioral Migraine Therapy: a Narrative Review. Current Pain and Headache Reports  (2018) doi:10.1007/s11916- 018-0718- 0. 
49. Müller, K. I., Alstadhaug, K. B. & Bekkelund, S. I. A randomized trial of telemedicine efficacy and safety for nonacute headaches. Neurology  (2017) doi:10.1212/WNL.0000000000004085.  
50. Akiyama, H. & Hasegawa, Y. A trial case of medical treatment for primary headache using telemedicine. 
Med. (United States)  (2018) doi:10.1097/MD.0000000000009891.  
51. Friedman, D. I., Rajan, B. & Seidmann, A. A randomized trial of telemedicine for migraine management. Cephalalgia  (2019) doi:10.1177/0333102419868250.  
52. Wells, R. E. & Loder, E. Mind/Body and Behavioral Treatments: The Evidence and Approach. Headache 
J. Head Face Pain (2012) doi:10.1111/j.1526- 4610.2012.02238.x.  
53. Matsuzawa, Y. et al.  Barriers to Behavioral Treatment Adherence for Headache: An Examination of 
Attitudes, Beliefs, and Psychiatric Factors. Headache (2019) doi:10.1111/head.13429.  
54. Wells, R. E., Bertisch, S. M., Buettner, C., Phillips, R. S. & McCarthy, E. P. Complementary and 
alternative medicine use among adults with migraines/severe headaches. Headache (2011) 
doi:10.1111/j.1526- 4610.2011.01917.x.  
55. Spruill, T. M. et al.  Telephone- based mindfulness training to reduce stress in women with myocardial 
infarction: Rationale and design of a multicenter randomized controlled trial. Am. Heart J.  (2018) 
doi:10.1016/j.ahj.2018.03.028.  
56. Carmody, J. & Baer, R. A. How long does a mindfulness -based stress reduction program need to be? 
A review of class contact hours and effect sizes for psychological distress. Journal of Clinical Psychology  
(2009) doi:10.1002/jclp.20555.  
57. Thompson, N. J. et al.  Expanding the efficacy of project UPLIFT: Distance delivery of mindfulness -based 
depression prevention to people with epilepsy. J. Consult. Clin. Psychol.  (2015) doi:1 0.1037/a0038404.  
58. Reilly -Spong, M., Reibel, D., Pearson, T., Koppa, P. & Gross, C. R. Telephone- adapted mindfulness -
based stress reduction (tMBSR) for patients awaiting kidney transplantation: Trial design, rationale and feasibility. Contemp. Clin. Trials  (2015) doi:10.1016/j.cct.2015.03.013.  
59. Cox, C. E. et al.  Development and preliminary evaluation of a telephone- based mindfulness training 
intervention for survivors of critical illness. Ann. Am. Thorac. Soc.  (2014) 
doi:10.1513/AnnalsATS.201308- 283OC.  
60. Keyworth, C. et al.  A mixed -methods pilot study of the acceptability and effectiveness of a brief 
meditation and mindfulness intervention for people with diabetes and coronary heart disease. Behav. 
Med.  (2014) doi:10.1080/08964289.2013.834865.  
61. Vettese, L. C., Toneatto, T., Stea, J. N., Nguyen, L. & Wang, J. J. Do mindfulness meditation participants 
do their homework? And does it make a difference? A review of the empirical evidence. Journal of 
Cognitive Psychotherapy  (2009) doi:10.1891/0889- 8391.23.3.198.  
62. Quarells, R. C. et al.  Depression self -management in people with epilepsy: Adapting project UPLIFT for 
underserved populations. Epilepsy Behav.  (2019) doi:10.1016/j.yebeh.2019.07.023.  
63. Seng, E. K. et al.  Does Mindfulness -Based Cognitive Therapy for Migraine Reduce Migraine- Related 
Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial. 
Headache (2019) doi:10.1111/head.13657.  
64. Day, M. A. Mindfulness -based cognitive therapy for chronic pain: A clinical manual and guide. 
Mindfulness -based cognitive therapy for chronic pain: A clinical manual and guide (2017). 
doi:http://dx.doi.org/10.1002/9781119257875.  
65. Singer, A. B., Buse, D. C. & Seng, E. K. Development and acceptability of a mindfulness -based cognitive 
therapy for migraine (MBCT -M) individual treatment protocol. Cephalalgia  (2017) 
doi:10.1177/0333102417719572.  
66. Seng, E. K. et al.  Response to mindfulness -based cognitive therapy for migraine in chronic and episodic 
migraine: Planned secondary analyses of a randomized clinical trial. Headache (2019) 
doi:http://dx.doi.org/10.1111/head.13549.  
67. Rosenberg L, S. E. The use of Mindfulness -Based Cognitive Therapy (MBCT) for migraine for the 
treatment of depressive symptoms in people with migraine: secondary analysis results from a phase 2b pilot randomized clinical trial. Headache 59, 7 (2019).  
Study number:  s20-01911   Page 37 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  68. Shallcross, A. J. et al.  Relapse prevention in major depressive disorder: Mindfulness -based cognitive 
therapy versus an active control condition. J. C onsult. Clin. Psychol.  83, (2015).  
69. Meadows, G. N. et al.  Mindfulness -based cognitive therapy for recurrent depression: A translational 
research study with 2- year follow -up. Aust. N. Z. J. Psychiatry  (2014) doi:10.1177/0004867414525841.  
70. Attkisson, C . C. & Zwick, R. The client satisfaction questionnaire. Psychometric properties and 
correlations with service utilization and psychotherapy outcome. Eval. Program Plann.  (1982) 
doi:10.1016/0149- 7189(82)90074- X. 
71. Segal, Z. V., Teasdale, J. D., Williams, J. M. & Gemar, M. C. The mindfulness -based cognitive therapy 
adherence scale: Inter -rater reliability, adherence to protocol and treatment distinctiveness. Clin. 
Psychol. Psychother.  (2002) doi:10.1002/cpp.320.  
72. Rush, A. J. et al.  The 16- item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating 
(QIDS -C), and self -report (QIDS -SR): A psychometric evaluation in patients with chronic major 
depression. Biol. Psychiatry  (2003) doi:10.1016/S0006- 3223(02)01866- 8. 
73. Roy E. Strowd, MD, MEd, Lauren Strauss, MD, Rachel Graham, Kristen Dodenhoff, Allysen Schreiber, 
Sharon Thomson, Alexander Ambrosini, Annie Madeline Thurman, Carly Olszewski, L. Daniela Smith, 
Michael S. Cartwright, MD, MS, Amy Guzik, MD, Rebecca Wells, M, C. T. Examining barriers and disparities during rapid implementation of outpatient teleneurology in rural Appalachia.  
74. Penzien DB, Smitherman TA, Bartley EJ, Rhudy JL, R. J. SDIH -4 (Brief) V4.0. (2016).  
75. First M  Gibbon M, Williams J, S. R. Structured Clinical Interview for DSM -IV. (Biometrics Research, 
New York State Psychiatric Institute, 1997).  
76. Chawla, N. et al.  The mindfulness -based relapse prevention adherence and competence scale: 
Development, interrater reliability, and va lidity. Psychother. Res.  (2010) 
doi:10.1080/10503300903544257.  
77. Segal, Z. V., Teasdale, J. D., Williams, J. M. & Gemar, M. C. The mindfulness -based cognitive therapy 
adherence scale: Inter -rater reliability, adherence to protocol and treatment distincti veness. Clin. 
Psychol. Psychother.  9, 131 –138 (2002).  
78. Crane, R. S. et al.  Development and Validation of the Mindfulness -Based Interventions - Teaching 
Assessment Criteria (MBI:TAC). Assessment  (2013) doi:10.1177/1073191113490790.  
79. Teasdale, J. D., Williams, J. M. G., Ridgeway, V. A., Soulsby, J. M. & Lau, M. A. Prevention of relapse 
/ recurrence in major depression by mindfulness -based cognitive therapy. J. Consult. Clin. Psychol.  68, 
615– 623 (2000).  
80. Langford, D. P. et al.  Back to the future – Feasibility of recruitment and retention to patient education 
and telephone follow -up after hip fracture: A pilot randomized controlled trial. Patient Prefer. Adherence 
(2015) doi:10.2147/PPA.S86922.  
81. Jacobson, G. P., Ramadan, N. M., Aggarwal, S. K. & Newman, C. W. The Henry Ford hospital headache disability inventory (HDI). Neurology  (1994) doi:10.1212/wnl.44.5.837.  
82. Devilly, G. J. & Borkovec, T. D. Psychometric properties of the credibility/expectancy questionnaire. J. Behav. Ther. Exp. Psychiatry  31, 73–86 (2000).  
83. Brooke, J. SUS -A quick and dirty usability scale. Usability Eval. Ind.  (1996).  
84. Pilkonis, P. A. et al.  Item banks for measuring emotional distress from the patient -reported outcomes 
measurement information system (PROMIS®): Depression, anxiety, and anger. Assessment  (2011) 
doi:10.1177/1073191111411667.  
85. Pilkonis, P. A. et al.  Validation of the depression item bank from the Patient -Reported Outcomes 
Measurement Information System (PROMIS®) in a three- month observational study. J. Psychiatr. Res.  
(2014) doi:10.1016/j.jpsychires.2014.05.010.  
86. Cole, J. C., Lin, P. & Rupnow, M. F. T. Validation of the Migraine- Specific Quality of Life Questionnaire 
version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual. Life Res.  (2007) 
doi:10.1007/s11136- 007-9217- 1. 
  
Study number:  s20-01911   Page 38 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  17 Appendix 1. Suicide Safety Plan  
All RAs  will be required to complete a suicide assessment and prevention training sponsored by the Suicide 
Prevention Resource Center ( https://zerosuicidetraining.edc.org/ ). A ll research personnel will be trained to 
conduct the below  protocol and will be regularly tested on their knowledge and understanding of the safety 
protocol.  
If a participant  reports being suicidal (e.g., verbally at any point during the study or endorses a “1”, “2”, or “3” 
on the survey items that ask about suicide and thoughts of hurting oneself), the research assistant (RA) will 
follow the procedures below.  
If the participant endorses suicidal ideation via phone/v i deo: 
RA will ask the following questions to assess risk.  
1. Are you currently under the care of a psychiatrist? Taking medication? Get details for physician name and medication name/how long person has been taking it, frequency of taking it.  
2. Approximately how frequently each day do you find yourself thinking about suicide? Rarely, maybe 1 time. 
Somewhat often, maybe a couple to a few. Often, on/off most of the day.  
 1) Rarely = not high risk  
 2) Somewhat often = elevated risk  
 3) Often = imminent risk  
3. Have you made any suicide attempts in the past? How would you describe your wish to die during your last attempt? (low, moderate, high)?  
1) Low = not high risk  
2) Moderate = elevated risk  
3) High= imminent risk  
4. Do you have a specific plan for how you may hurt yourself? If so, what is your plan? If so, when do you think you’ll act on your plan? If so, how confident are you that you’ll act on your plan?   
 1) No evidence for plan = not high risk  
 2) Evidence for  plan wit NO timing and NO confidence = elevated risk  
 3) Evidence for plan with timing and confidence = imminent risk  
5. Have you made preparations (e.g., writing a suicide note, buying a firearm and ammunition, etc.) for engaging in self -harm behaviors? If so, what have you done?   
 1) No evidence for preparations = not high risk  
 2) Evidence for preparations = imminent risk  
6. On a scale of 1- 10, '10' being very suicidal, how suicidal (how high is your wish to die) right now?  
 1) 1-2 = not high risk  
Study number:  s20-01911   Page 39 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019   2) 3-4 = elevated risk  
 3) 5 or higher = imminent risk  
7. On a scale of 1- 10, '10' being very likely, how likely is it that you will make an attempt in the next 24 hours?  
 1) 1-2 = not high risk  
 2) 3-4 = elevated risk  
 3) 5 or higher = imminent risk  
8. How confident are you '10' being very confident, about keeping yourself safe for the next 24 hours?  
 1) 1-2 = not high risk  
 2) 3-4 = elevated risk  
 3) 5 or higher = imminent risk  
9. Do you live with anyone or alone? Inquire about relationship with housemates.  
 
If the participant endorses suicidal ideation via online survey:  
Any participant who endorses the suicidal ideation item via survey is automatically routed to the BSS 
using branch- logic. The online survey platform will send an ‘Email Trigger’ to the study email address, 
which is monitored daily. The Email Trigger is sent with high priority and includes responses to 
questions on both the depression measure (e.g., QIDS -16) and the BSS. We additionally include 
alternative ‘end of survey elements’ for participants who endorse the suicide item online, whereby participants are provided a mental health resource sheet that includes the suicide hotline and referrals to local mental health services.  
The RA will examine the participant’s BSS. First, a total score will be calculated and a note will be made of whether or not the total score is under or over 11. Scores over 11 indicate a notable risk level. Second, 5 key items: 12, 15, 16, 18, and 21 will be closely examined. There is greater cause for concer n if a participant 
endorses a “2” for any of these items rather than a “0” or a “1.”   
1. If the score on the BSS is under 11 and the above 5 items are not noteworthy, the person is not at high 
risk for suicide and no immediate action is needed. The participant will, however, be given a resource sheet with referral information to local mental health clinics at each site. This sheet has information about how to contact mental health resources should they feel they need to do so, including emergency suicide hotl ine numbers.  
2. If the score on the BSS is 11 or higher and/or the 5 items are noteworthy, the RA will conduct continued risk assessment over the phone and ask the participant the following questions:  
a. Do you have a specific plan for how you may hurt yourself? If so, what is your plan? If so, when do you think you’ll act on your plan? If so, how confident are you that you’ll act on your plan?   
b. Have you made preparations (e.g., writing a suicide note, buying a firearm and ammunition, etc.) for engaging in self -harm behaviors? If so, what have you done?   
Response to risk levels:  
Study number:  s20-01911   Page 40 
Version date:  3/8/2022    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and NYU Langone Health.  Do not disclose or use except as authorized in 
writing by the study sponsor  
Behavioral Intervention Template Version: 11 January 2019  • I f the participant is in imminent danger  of hurting him/herself (i.e., has a plan, intent, means and 
cannot keep him/herself safe for 24 hours):  
a. T he RA will confirm additional information such as the participant’s location and whether they 
are living alone. If the participant indicates that they live with another adult, RA will acquire the 
name and contact information for this pers on. 
b. The RA will immediately notify the licensed neurologist Co- I and PI. If neither are available, the 
RA will contact the participant’s PCP and/or treating psychiatrist to arrange for further evaluation and/or an emergency appointment.  
c. If the RA is unable to reach Co- I, PI, PCP or psychiatrist, the RA will attempt to convince the 
participant to voluntarily seek help from an emergency facility and will assist the participant with the process of admitting him/herself to the hospital.  
d. If the participant is uncooperative or unwilling to go to an emergency facility, the RA will call 911 for the purposes of transporting a high- risk participant to the ER for evaluation. Law 
enforcement will not be involved in involuntary hospital admission.  
e. In the event a participant is hospitalized, the PI and Co- I will evaluate the participant’s 
circumstances and stability (based on length of hospitalization, need for intensive treatment, etc.) to determine whether the participant is fit to continue with the study.  
f. If a prospective participant endorses high- risk items on the BSS during pre- screening (before 
we have collected data on provider information) *and* is unable to be reached by phone or by email, the RA will consult the participant’s health record to determine PCP  contact information. 
If there is no PCP listed, the RA will contact the participant’s psychiatrist. If neither a PCP nor psychiatrist is listed in the health record, the RA will contact the participant’s neurologist  to 
inform him/her/them about the prospective participant’s suicide risk .  
 
• I
f the participant is at an elevated, but not imminent, risk for suicide , the RA will call the treating 
physician (if applicable) and will orchestrate an amplified monitoring procedure under the supervision of the physic ian, PI, and Co -I. Specifically, the RA will help the participant create a coping card (i.e., an 
index card, to be carried with the participant at all times, that outlines several coping skills – like calling 
a loved one or going for a walk – that have helped the participant cope with distress in the past, and 
lists emergency contact numbers in the case of acute suicide risk), and arrange to call the participant 1 day later to reassess suicide risk.  
The licensed neurologist Co- I
  will be notified of every instance of suicidal ideation, will be available for higher 
level suicide risk assessments, and can interface with psychiatry (in case of the need for psych ER assessment and inpatient psychiatric hospitalization) . 
After this response plan is implemented, a  report of the event will be made to the applicable IRB  and all 
members of the study team. In compliance with applicable regulations any unanticipated problem or serious 
adverse event should be reported to the IRB within 24 hours of the event.   
 